Radius  Health,  Inc. Confidential  
Study  BA058 -05-022, Amendment  1, 18 March  2019  Page  1 of 62  Disclosure  Statement  
This document contains information that is confidential and proprietary to Radius Health, Incorporated 
(Radius).  This information is being provided to you solely for the purpose of evaluation and/or conducting a  
clinical trial for Radius. You may disclose the contents of this document only to study personnel under your  
supervision and/or  to your institutional review  board(s)  or ethics  committee(s)  who need to know  the contents  
for this purpose  and who have  been  advised  on the confidential  nature of  the document.  CLINICAL STUDY PROTOCOL  
AMENDMENT  1 
A Prospective, Single Arm Study to Evaluate the PK, PD and Usability of 
Abal
oparatide -sMTS in Postmenopausal Women with Low Bone Mineral  
Density  
This study will be conducted according to the protocol and in compliance with Good Clinical 
Practice (GCP), the ethical principles stated in the Declaration of Helsinki, and other applicable 
regulatory requirements.  
Protocol Number:  Protocol BA058-05-022 
Protocol Date: 18 March 2019 
IND Number:  73,176 
Study Sponsor:  Radius Health, Inc. (Radius) 
Tel: (617) 551-4700; Fax:
Contract Research  
Or
ganization (CRO)  Pharmaceutical Research Associates, Inc 
9755 Ridge Drive  
Lenexa,  Kansas  66219 
Version  number  Version  date 
Original  21 January  2019  
Amendment  1 18 March  2019  NCT #[STUDY_ID_REMOVED]

Radius  Health,  Inc. Confidential  
Study  BA058 -05-022, Amendment  1, 18 March  2019  Page  2 of 62   
  
TABLE OF CONTENTS  
TABLE OF  CONTENTS  .................................................................................................................2 
LIST  OF TABLES  ...........................................................................................................................6 
LIST  OF FIGURES  .........................................................................................................................6 
LIST  OF ABBREVIATIONS  ..........................................................................................................7 
SYNOPSIS  .......................................................................................................................................9 
1. INTRODUCTION  ......................................................................................................16 
1.1. Background .................................................................................................................16 
1.1.1. Disease and Study Drug  Background .........................................................................17 
1.1.2. Study Drug  Development  ...........................................................................................18 
1.1.2.1. Nonclinical  Studies .....................................................................................................18 
1.1.2.2. Clinical Studies  ...........................................................................................................18 
1.2. Study Rationale  ...........................................................................................................20 
1.3. Dose  Rationale  ............................................................................................................21 
2. STUDY OBJECTIVES AND ENDPOINTS ..............................................................22 
2.1. Objective  .....................................................................................................................22 
2.2. Primary  Endpoint ........................................................................................................22 
2.3. Secondary  Endpoints ..................................................................................................22 
2.3.1. Pharmacodynamic (PD)  Endpoints .............................................................................22 
2.3.2. Other  Endpoints ..........................................................................................................22 
2.3.3. Safety  and Tolerability  Endpoints ..............................................................................22 
3.
 STUDY DESIGN  .......................................................................................................23 
3.1. Description  of the Study Design  .................................................................................23 
4. SELECTION OF  STUDY POPULATION  ................................................................24 
4.1. Inclusion Criteria  ........................................................................................................24 
4.2. Exclusion Criteria  .......................................................................................................25 
4.3. Subject  Withdrawal or Termination  ...........................................................................26 
4.3.1. Reasons  for Withdrawal  or Termination  ....................................................................26 
4.3.2. Handling of Subject Withdrawals or Terminations  ....................................................27 
4.4. Concomitant Medications  ...........................................................................................27 
4.5. Prohibited Medications  ...............................................................................................27 
4.6. Premature Termination or Suspension of Study .........................................................28 
Radius  Health,  Inc. Confidential  
Study  BA058 -05-022, Amendment  1, 18 March  2019  Page  3 of 62   
 4.7. Temporary  Suspension of Treatment ..........................................................................28 
5. STUDY DRUG ADMINISTRATION AND MANAGEMENT ................................29 
5.1. Study Medication  ........................................................................................................29 
5.1.1. Abaloparatide- sMTS  ...................................................................................................29 
5.2. Packaging, Labeling  and Storage ...............................................................................29 
5.2.1. Packaging  and Labeling  ..............................................................................................29 
5.2.2. Storage ........................................................................................................................29 
5.3. Study Medication Administration  ...............................................................................29 
5.4. Treatment  Assignment ................................................................................................30 
5.5. Dosing and Administration  .........................................................................................30 
5.6. Treatment  Compliance ................................................................................................30 
5.7. Drug  Accountability  ...................................................................................................31 
6. STUDY PROCEDURES AND SCHEDULE  ............................................................32 
6.1. Study Procedures  ........................................................................................................32 
6.1.1. Study Specific Procedures ..........................................................................................32 
6.2. Study Schedule ...........................................................................................................32 
6.2.1. Schedule of Assessments  and Procedures ..................................................................32 
6.2.2. Informed  Consent Process ..........................................................................................36 
6.2.3. Assigning Subject Numbers .......................................................................................36 
6.2.4. Subject  and Disease Characteristics  ...........................................................................36 
6.2.5.
 Screening  Period (Visit 1; Days  -67 to -8) .................................................................36 
6.2.6. Pre-treatment  Period (Days -7 to -1) ..........................................................................37 
6.2.7. Treatment  Period  ........................................................................................................37 
6.2.7.1. Visit 3 (Day  1) ............................................................................................................37 
6.2.7.2. Visit 4 (Day  15) ..........................................................................................................38 
6.2.7.3. Visit 5 / End of Treatment (Day  29) ...........................................................................39 
6.2.8. Visit 6/Follow up (Day  36) .........................................................................................40 
6.2.9. Unscheduled Visit .......................................................................................................40 
6.3. Vital Signs and Physical Examinations ......................................................................40 
6.4. 12-Lead  Electrocardiogram  ........................................................................................41 
6.5. Laboratory Evaluations ...............................................................................................41 
6.5.1. Clinical Laboratory Evaluations .................................................................................41 
6.5.2. Serum  Markers of Bone Metabolism ..........................................................................42 
Radius  Health,  Inc. Confidential  
Study  BA058 -05-022, Amendment  1, 18 March  2019  Page  4 of 62   
 6.5.3. Specimen  Preparation, Handling and Storage ............................................................42 
6.6. Imaging Procedures  ....................................................................................................42 
6.6.1. Dual Energy X- ray Absorptiometry  (DXA)  ...............................................................42 
6.6.2. Local  Tolerance  ..........................................................................................................43 
6.6.2.1. Investigator assessment of signs of local tolerance  ....................................................43 
6.6.2.2. Subject  assessment of symptoms of local tolerance ...................................................43 
6.6.3. Residual Drug .............................................................................................................43 
6.6.4. Assessment  of Patch Adhesion ...................................................................................44 
6.6.5. Assessment  of Subject Reported Outcomes ...............................................................44 
6.7. Discontinuation from the  Study ..................................................................................45 
6.7.1. Withdrawal  of Consent ...............................................................................................45 
6.7.2. Early  Study Termination  .............................................................................................45 
7. ADVERSE  EVENT  AND  SERIOUS  ADVERSE  EVENT  
DOCUMENTATION  .................................................................................................46 
7.1. Evaluation of Safety ...................................................................................................46 
7.1.1. Adverse Event .............................................................................................................46 
7.1.2. Serious Adverse Event (SAE)  ....................................................................................47 
7.1.3. Recording an Adverse  Event ......................................................................................47 
7.1.3.1. Serious and Unanticipated Adverse Device Effects for  Abaloparatide- sMTS  ...........49 
7.1.4. Serious Adverse Event Reporting ...............................................................................49 
7.1.5. D evice Reporting ........................................................................................................50 
7.1.6. Follow-up of Adverse Events  .....................................................................................50 
7.1.7. Overdose .....................................................................................................................50 
7.1.8. Regulatory Agency,  Institutional Review  Board, and Site Reporting ........................50 
7.2. Study Completion and Post-Study Treatment  .............................................................50 
7.3. Lost to Follow-up .......................................................................................................51 
8. STATISTICAL  CONSIDERATIONS  .......................................................................52 
8.1. Statistical and Analytical Plans  ..................................................................................52 
8.2. Statistical Hypotheses .................................................................................................52 
8.3. Analysis Datasets  ........................................................................................................52 
8.3.1. Population for Analysis ..............................................................................................52 
8.4. Description  of Statistical Methods  ..............................................................................52 
8.4.1. General  Approach .......................................................................................................52 
Radius  Health,  Inc. Confidential  
Study  BA058 -05-022, Amendment  1, 18 March  2019  Page  5 of 62   
 8.4.2. Analysis of the Primary  Endpoint ...............................................................................52 
8.4.3. Analysis of Secondary Endpoints ...............................................................................53 
8.4.4. Safety  Analyses ...........................................................................................................55 
8.4.5. Adherence and Retention Analyses ............................................................................55 
8.4.6. Baseline Descriptive  Statistics  ....................................................................................55 
8.4.7. Interim Analyses  .........................................................................................................56 
8.4.8. Additional Subgroup Analyses  ...................................................................................56 
8.4.9. Multiple  Comparison/Multiplicity  ..............................................................................56 
8.4.10. Tabulation of Individual Response Data  ....................................................................56 
8.4.11. Exploratory Analyses  ..................................................................................................56 
8.5. Sample  Size Calculation  .............................................................................................56 
8.6. Measures  to Minimize  Bias  ........................................................................................56 
8.7. Enrollment/Randomization/Masking  Procedures  .......................................................56 
9. ADMINISTRATIVE  REQUIREMENTS  ..................................................................57 
9.1. Ethical  Considerations ................................................................................................57 
9.2. Subject  Information and Informed Consent ...............................................................57 
9.3. Investigator Compliance .............................................................................................57 
9.4. Access  to Records .......................................................................................................57 
9.5. Subject  and Data Confidentiality  ................................................................................58 
9.6. Research  Use of Stored  Human Samples,  Specimens, or Data  ..................................58 
9.7.
 Data Quality  Assurance  ..............................................................................................58 
9.8. Monitoring ..................................................................................................................59 
9.9. Data Collection and Management Responsibilities  ....................................................59 
9.10. Study Records Retention  ............................................................................................60 
9.11. Publication  and Data Sharing  Policy  ..........................................................................60 
10. LITERATURE REFERENCES  ..................................................................................61 
Radius  Health,  Inc. Confidential  
Study  BA058 -05-022, Amendment  1, 18 March  2019  Page  6 of 62   
  
LIST  OF TABLES  
Table 1: Schedule of Assessments ............................................................................................33 
Table 2: Clinical Laboratory  Tests ............................................................................................41 
 
 
 
LIST  OF FIGURES  
Figure 1: Study Design  ...............................................................................................................23 
Radius  Health,  Inc. Confidential  
Study  BA058 -05-022, Amendment  1, 18 March  2019  Page  7 of 62   
  
LIST  OF ABBREVIATIONS  
 
Abbreviation Term  
 
°C Degree Celsius  
°F Degree Fahrenheit  
µg Microgram  
µL Microliter  
µmol Micromole  
AE Adverse event  
AESI  Adverse event  of special  interest  
AUC  Area under the concentration- time curve 
BMD  Bone mineral density  
bpm Beats  per minute  
BSAP  Bone- specific alkaline  phosphatase 
cAMP  Cyclic  adenosine monophosphate 
cm Centimeter  
Cmax Maximum plasma  concentration  
CRF  Case report  form  
CSR  Clinical study report  
DXA  Dual energ y X-ray absorptiometry 
ECG  Electrocardiogram  
eCRF  Electronic  case report  form  
EDC  Electronic  data capture  
EOT  End of Treatment  
g Gram  
GCP  Good clinical  practice  
GLP  Good laboratory practice  
GMP  Good manufacturing practice  
Geo Geometric  
HRT  Hormone replacement  therapy  
IB Investigator's Brochure  
IC Informed  consent 
ICF Informed  consent form  
IRB Institutional review  board 
IU International unit 
IV Intravenous 
kg Kilogram 
L Liter  
MedDRA  Medical  dictionary for regulatory activities  
mg Milligram 
Radius  Health,  Inc. Confidential  
Study  BA058 -05-022, Amendment  1, 18 March  2019  Page  8 of 62   
  
 
 
Abbreviation Term  
 
mL Milliliter  
mmHg  Millimeter  of mercury  
ng Nanogram 
PA Posterior- anterior  
PD Pharmacodynamic 
pg Picogram  
PK Pharmacokinetic  
PMO  Post-menopausal Osteoporosis 
PT Prothrombin time  
PTH  Parathyroid hormone 
PTHrP  Parathyroid hormone related  peptide 
PTT Partial  thromboplastin time 
SAE  Serious adverse event  
SAP Statistical Analysis Plan 
SC Subcutaneous 
SD Standard  deviation 
SE Standard  error  
sMTS  Solid  microstructured  transdermal  system  
SOA Schedule of Assessments  
SOC  System  organ class  
s-PINP  Serum  procollagen type 1 N propeptide 
TEAEs  Treatment  emergent  adverse events  
TSH  Thyroid stimulating  hormone 
TSQM -9 Treatment  satisfaction questionnaire  for medication  short form  
UADE  Unanticipated  adverse device effect  
ULN  Upper limit of normal 
WHO  World  Health  Organization 
Radius  Health,  Inc. Confidential  
Study  BA058 -05-022, Amendment  1, 18 March  2019  Page  9 of 62  
  
SYNOPSIS  
 
Name  of Sponsor/Company:  
Radius Health,  Inc. (RADIUS)  
Name  of Investigational Product:  
Abaloparatide- solid  microstructured  transdermal  system  (sMTS)  (formerly  called  BA058) 
Name  of Active  Ingredient:  
Abaloparatide 
Protocol Number:  
BA058-05-022 Phase:  1b Country:  United  States  
Title  of Study:  
A Prospective, Single Arm Study to Evaluate the PK, PD and the Usability of Abaloparatide- sMTS in  
Postmenopausal Women with Low Bone Density  
Study  center(s):  Pharmaceutical  Research  Associates, Inc , Lenexa,  Kansas  
Objectives:  
Primary:  
• The primary objective of this study is to evaluate the ability of subjects to self- administer  
abaloparatide- sMTS  (300 µg) over a period of 29 days based on pharmacokinetics (PK) and 
pharmacodynamic (PD) markers.  
Secondary:  
• The secondary objective is to evaluate the usability of abaloparatide- sMTS as measured by  
incidence of user errors,  overall  subject acceptability,  preference,  satisfaction  and adherence 
to study therapy. 
• Other  secondary  objectives include an evaluation of overall  safety  and tolerability  of 
abaloparatide- sMTS  as assessed  by treatment  emergent adverse  events (TEAEs),  vital signs  
(orthostatic blood pressure, pulse rate, body temperature, and respiration rate), ECGs, 
laboratory tests (chemistry,  hematology, urinalyses)  and local tolerance.  
Study  Design  and Methodology:  
In this study, the effectiveness of subjects to self -administer 300 µg abaloparatide -sMTS once-daily on 
the thigh for 5 minutes for a period of 29 days will be assessed through PK and PD (bone biomarker) 
analyses. Before the start of treatment, subjects wi ll receive training on abaloparatide -sMTS application.  
During the study, the subjects will record their user experience, incidence of user errors; the subject and investigator will both assess local tolerance (symptoms [subject] and signs [investigator] of local skin 
reactions). On study visit days, subjects will self- administer abaloparatide -sMTS and will have blood 
samples drawn for PK and PD measurements, including an evaluation of subject preference parameters.  
The detailed  study design  will be as follo ws: 
Screening  Period  (Days - 67 to -8): 
The initial period  will be the Screening Period  where  clinical evaluations will be done from  Days  -67 to 
-8 which  includes  signing  of the informed  consent, medical  history,  comprehensive  physical  
Radius  Health,  Inc. Confidential  
Study  BA058 -05-022, Amendment  1, 18 March  2019  Page  10 of 62  
  
examination, measurement of vital signs, ECG, hematology, serum chemistry (including calcium,  
albumin, and phosphorus), coagulation tests, urinalysis, 25- hydroxyvitamin D, 1,25-dihydroxyvitamin 
D, and serum pregnancy testing if needed. Urine will be collected for urinalysis and urine drug and 
alcohol screen. In addition, a 24 hour urine collection will begin on Day -8 and p atients will bring in  
their sample on Day  -7. 
If a subject does not have a recent (within 12 months) bone mineral density (BMD) scan, a scan will be performed to ensure the subject meets the BMD requirement. Note: Every effort will be made to enroll  
subjec ts with a T -score of -2.0 or lower but > -5.0; for those with scores higher than -2.0, preference 
should be given to subjects with lower  BMD scores.  
Pre-Treatment  Period  (Days -7 to -1): 
Based  on screening  evaluations,  eligible  subjects will enter  a 1-week  pre-treatment  period where  vitamin  
D and calcium supplementation will be initiated.  
Treatment Period,  Day  1: 
Subjects will be admitted to the clinical research facility on Day 1 of the treatment period. Subjects who continue to meet the study criteria will undergo a symptom- directed physical exam and assessments of 
vital signs, ECG, updated medical history including concomitant medications, and review of any adverse 
events (AEs). Other predose assessments include: blood collections for PK, hema tology, serum  
chemistry (including calcium, albumin, and phosphorus), coagulation tests, urinalysis, cyclic adenosine monophosphate (cAMP), and baseline measurements of s -PINP. Urine will be collected for urinalysis  
and for drug and alcohol testing. The application site will be prepared and cleaned, and predose  
assessment of  the application  site will  be done by the investigator and  the subject.  
Immediately before initial dosing (Day 1), the subject will be trained in abaloparatide -sMTS application  
and instructed how to perform a self- assessment of symptoms of local skin reaction of the application 
site. After the training, the subject will assess the application site for symptoms of local skin reactions prior to application of abaloparatide-sMTS and will the n self -administer the study drug. A subject diary 
will be provided for recording of user errors in abaloparatide-sMTS application, patch adhesion, and 
assessment of  local  tolerance (symptoms of local  skin  reactions).  
Self-assessments of symptoms of local skin reaction will be performed by the subject 5 minutes after  
application of abaloparatide-sMTS and 1 hour after application of abaloparatide-sMTS on the day of 
clinic visits. Subject will also be instructed to conduct this assessment of symptoms of local skin  
reactions, user errors, and an assessment of patch adhesion, beginning Day 1 until Day 29 or end of 
treatment (EOT)  visit.  
Investigators will perform an assessment of signs of local skin reaction on the application site prior to abaloparatide-sMTS application, 5 minutes after application (ie, immediately upon removal of 
abaloparatide- sMTS),  and 1 hour after abaloparatide- sMTS  application. 
Subject preference for treatment attributes, and acceptability will also be assessed by the subjects.  
Pharma cokinetic measurements will be assessed at 10 minutes, 20 minutes, 30 minutes, 1, 1.5, 2, 3 and 
4 hours after application of abaloparatide- sMTS. Pulse rate will be recorded 15 minutes after 
abaloparatide- sMTS application with a repeat ECG taken 1 hour after abaloparatide- sMTS application.  
Blood will be drawn for assessment of cAMP at 30 minutes after abaloparatide- sMTS application and  
for assessment of serum calcium, albumin, and phosphorus at 4 hours after abaloparatide- sMTS  
application. 
Following completion of Day 1 study  activities,  the subject will  be sent  home with  the diary  and a 
2-week  supply  of abaloparatide -sMTS  for self-administration  together  with locally  sourced  vitamin  D 
Radius  Health,  Inc. Confidential  
Study  BA058 -05-022, Amendment  1, 18 March  2019  Page  11 of 62  
  
and calcium supplements. The subject will be instructed to self -administer abaloparatide -sMTS every  
day, take the vitamin D and calcium supplements, and complete the subject diary entries as outlined  
above. 
Treatment Period,  Day  15 and Day  29/EOT:  
On Days 15 and 29, the subject will be readmitted to the clinical research facility. A review of AEs and 
concomitant medications will be conducted and predose assessments will include: symptom -directed  
physical exam, vital sign measurements, ECG, blood collections for PK, hematology, serum chemistry 
(including calcium, albumin, and phosphorus), coagulation tests, urinalysis, cAMP, and s- PINP.  
Following completion of the predose assessments, the subject will self-administer the product. Used 
abaloparatide- sMTS  and swab for residual drug and swab residuals will be  collected.  
Symptoms of local skin reaction will be assessed by the subject (prior to application of abaloparatide sMTS, 5 minutes after application (ie , immediately upon removal of abaloparatide -sMTS), and 1 hour 
after abaloparatide- sMTS application) and recorded in the subject diary. The subject will also assess 
patch adhesion and user errors. Subjects will also complete user experience assessments incl uding: 
treatment satisfaction questionnaire for medication short form (TSQM9) Global Satisfaction and  
convenience domains; 5-point Likert- like scale of acceptability; and subject preference for treatment  
attributes.  
The study staff will review the prior entries in the diary and provide additional training on how to 
complete the diary, as needed. In addition, the study staff will conduct an investigator assessment of 
signs  of local  skin reactions.  
Post application assessments will include blood draws for cAM P, serum calcium, albumin, and 
phosphorus urinalysis. PK measurements will be assessed 10 minutes, 20 minutes, 30 minutes, 1, 1.5, 2, 3, and 4 hours after abaloparatide-sMTS application. 
On Day 15, the subject will be resupplied with abaloparatide- sMTS, an d vitamin D and calcium  
supplements. Subjects will be instructed to continue recording user experience, acceptability and 
preferences for treatment attributes, user errors, patch adhesion, symptoms of local skin reactions, and  
information  on study drug accountability in the  subject  diary. 
Follow -up Visit  (Day  36) 
A follow up visit  7-days following Visit  5/EOT  can be done either  in clinic  or remotely  via a phone 
follow up. Assessment  of local  tolerance will be  conducted for subjects  with  ongoing signs  or symptoms  
of local  skin reactions  and a review of  AEs and  concomitant  medications will  be done.  
Number  of subjects (planned):  
Approximately 22 subjects will be enrolled and treated to ensure a minimum of 18 subjects complete the 29-day treatment and study procedures. Note: Every effort will be made to enroll subjects with a T- score 
of -2.0 or lower but > - 5.0; for those with scores higher than - 2.0, preference should be given to subjects  
with lower  BMD scores.  
Diagnosis and main criteria for inclusion and exclusion criteria:  
Inclusion  criteria:  
Subjects will be  included in  the study if they meet  all of  the following inclusion criteria:  
1. Healthy  ambulatory  female  from  50 to 85 years of age  (inclusive)  
Radius  Health,  Inc. Confidential  
Study  BA058 -05-022, Amendment  1, 18 March  2019  Page  12 of 62  
  
2. Postmenopausal for at least 2 years. Postmenopausal status will be established by a history of  
amenorrhea for at least 2 years, and negative serum pregnancy test or an elevated serum follicle- 
stimulating  hormone (FSH)  value of  ≥ 30 IU/L.  
3. BMD T- score based on the female reference range < -1.0 and >- 5.0 at the lumbar spine (L1–L4)  
or hip (femoral neck or total hip) by dual energy X- ray absorptiometry (DXA). Note: Every 
effort will be made to enroll subjects with a T -score of -2.0 or lower but > -5.0; for those with 
scores higher than  -2.0, preference  should be given to  subjects with  lower  BMD scores.  
4. Good general health as determined by medical history and physical examination (including vital 
signs), has a body mass index of up to 33 kg/m2, and i s without evidence of clinically significant 
abnormality that may increase the risk associated with study participation or investigational  
product administration, or may interfere with compliance or the interpretation of study results, 
and would  make  the subject  inappropriate for this  study in the opinion of the  Investigator 
5. Serum calcium (albumin -corrected), intact parathyroid hormone (PTH), serum phosphorus, 
alkaline phosphatase, and thyroid stimulating hormone (TSH) values all within the normal range 
during the Screening Period.  Subjects with  minor elevations  or reductions in serum  calcium  may 
be enrolled if serum ionized calcium is normal. Any subject with an elevated alkaline  
phosphatase value, and who meets all other entry criteria would be requir ed to have a normal  
bone- specific  alkaline phosphatase  to be enrolled  
6. Serum  25-hydroxyvitamin D values ≥ 20 ng/mL.  
7. Resting  12-lead electrocardiogram  at screening  shows  no clinically  significant  abnormality. 
8. Systolic  blood pressure is ≥ 100 and ≤ 155  mmHg,  diastolic blood pressure is ≥ 40 and 
≤ 95 mmHg, and heart rate is ≥ 45 and ≤ 100 bpm  (taken sitting)  
9. No clinically  significant abnormality  of serum  hemoglobin, hematocrit,  white  blood  cells,  and 
platelets, or usual serum chemistry, including electrolytes, renal function, liver function and serum proteins, that might be expected to interfere with the subject’s health and/or medical  
treatment during  the study 
10. Read,  understood, and signed  the written  informed  consent  form  
11. Hemoglobin  value ≥ 12.0 g/dL. 
Exclusion criteria:  
Subjects who meet any  of the following  exclusion criteria will be  excluded from  the study: 
1. History  of bone disorders  (eg, Paget’s  disease)  other than postmenopausal osteoporosis 
2. History  of prior  external  beam  or implant radiation  therapy  involving the skeleton, other than 
radioiodine 
3. H
istory of Cushing’s disease, hypo- or hyper -parathyroidism or malabsorptive syndromes within  
the past  year  
4. History  of significantly  impaired  renal function (serum  creatinine > 177 μmol/L  or 
> 2.0 mg/dL). If serum  creatinine  is > 1.5 and ≤ 2.0  mg/dL,  the calculated  creatinine  clearance 
(Cockcroft- Gault)  must  be ≥ 37 mL/min  
5. History of any cancer within the past 5 years (other than basal cell or squamous cancer of the skin)  
6. History  of osteosarcoma  at any time 
7. History  of nephrolithiasis  or urolithiasis  within  the past 5 years 
Radius  Health,  Inc. Confidential  
Study  BA058 -05-022, Amendment  1, 18 March  2019  Page  13 of 62  
  
8. Application site (thigh) compromised by scars, inflammation or skin conditions to an extent that  
may compromise uniformity of abaloparatide -sMTS application or drug delivery (nevi, plaques, 
tattoos,  scars, piercing, etc.)  
Medication- related  exclusion  criteria:  
9. Known  history of hypersensitivity  to any of the test materials  or related  compounds 
10. Prior therapeutic treatment with PTH - or PTH -related peptide (PTHrP) -derived drugs, or bone 
anabolic drugs including abaloparatide, teriparatide, or PTH(1-84). Subjects who received 
abaloparatide in prior Phase 1 studies are not  excluded 
11. Prior treatment wi th intravenous bisphosphonates at any time or oral bisphosphonates within the 
past year  (12 months). Subjects who have received  a short  course  of oral bisphosphonate therapy 
(3 months or less) may be enrolled as long as the treatment occurred 6 or more months prior to enrollment  
12. Treatment  with  fluoride or strontium  in the past 5  years  or prior  treatment with  gallium nitrate  or 
bone- acting  investigational agents at  any time 
13. Prior  treatment with  calcitonin  or tibolone in the past 6 months 
14. Treatment  with  denosumab  within  the past  18 months 
15. Treatment with anticonvulsants that affect vitamin D metabolism (phenobarbital, phenytoin,  
carbamazepine or primidone) or  with chronic heparin  within  the 6 months prior  to the Screening  
Period 
16. Treated with anabolic steroids or calcineurin inhibitors (cyclosporin, tacrolimus) within the past 
90 days. 
17. Prior treatment with selective estrogen receptor modulators (except hormone replacement  
therapy) within  past 6 months or  daily  treatment  with  oral, intranasal,  or inhaled  corticosteroids  
within the 12 months prior to the Screening Period. Occasional use of all corticosteroids (for seasonal  allergies  or asthma) is  not exclusionary. Use  of low dose  oral corticosteroids 
(eg, ≤ 5 mg/day of prednisone or the relative equivalent dose of another corticosteroid) is also 
not exclusionary. 
18. Participation  is another clinical  trial with  any investigational drug  or device within  3 months or 
5 half- lives of the invest igational drug (if known), whichever is longer, of study drug 
administration. 
Lifestyle -related  exclusion  criteria:  
19. Abnormal nutritional status as assessed by the investigator including abnormal diets and  
excessive or unusual vitamin or herbal intakes; vit amin D intake of ≥ 4,000 IU/day or vitamin A  
intake of ≥ 10,000 IU/day. Short term use of high doses of vitamin D to bolster endogenous  
vitamin  D levels  for study entry  during the screening  period is not  exclusionary  
20. Active drug or alcohol dependence or abuse (excluding tobacco or medicinal or recreational  
marijuana use where legal unless there is evidence of abuse) within 12 months of the screening  
period; or evidence  of such abuse (in the opinion of the investigator). 
Investigational product,  dosage and mode  of administration:  
The 300 µg abaloparatide-sMTS will be applied to the thigh and worn for 5 minutes once a day, according  to the Instructions for Use  
Duration of treatment:  
Radius  Health,  Inc. Confidential  
Study  BA058 -05-022, Amendment  1, 18 March  2019  Page  14 of 62  
  
The study  will consist of  a Screening  Period,  a 1-week  Pre-treatment period,  a treatment period  of 
29 days and a 7-day follow-up period. Any subject that has a reported treatment-related AE during the 
study will be  followed  until complete  resolution or stabilization,  or until the subject is lost to follow -up. 
Reference therapy, dosage and mode  of administration:  
N/A 
Criteria  for evaluation: 
Pharmacokinetics/  Pharmacodynamics:  
Pharmacokinetics Measurements:  
Individual plasma concentrations of abaloparatide will be tabulated by visit and sampling time and 
summarized descriptively. Individual and summary profiles will also be plotted. The plasma concentration -time profiles of abaloparatide will be analyzed using non-compartmental methods, and 
calculations will be made using the actual time since dose. Data permitting, the PK parameters 
maximum plasma concentration (C
max), time of maximum observed plasma concentration (t max), area  
under the plasma concentration-t ime curve (AUC0 -t), area under the curve extrapolated to infinity 
(AUC0 -inf), elimination rate constant (λz), and half -life (t1/2) will be derived. Derived PK parameters  
will be listed and summarized by visit. Descriptive statistics (mean, standard deviation [SD], coefficient  
of variation [CV%], minimum, median, maximum, geometric mean, and geometric CV%) will be 
provided by visit (Day  1, Day 15, and Day 29). 
Pharmacodynamic Measurements:  
Measurements  of s-PINP  will be  summarized  descriptively  for each  visit.  Changes and percent changes  
from baseline, as well as ratio of post -baseline value over baseline value, will be summarized  
descriptively with 90% confidence interval by visit. Individual and summary profiles will also be plotted. 
The actual values, change from baseline values, and the percentage change from baseline values for  
serum  calcium  (albumin -corrected),  serum  phosphorus, and cAMP  will be summarized  using descriptive 
statistics  by visit and timepoint. 
User experience  measurements:  
User  errors  and user preference data will  be tabulated  and summarized  descriptively.  
For the Treatment Satisfaction Questionnaire for Medication – Short Form (TSQM -9), only the global 
satisfaction and convenience domains will be assessed. The mean TSQM- 9 score (±standard error [SE])  
for each  domain  will be tabulated  for Day  15 and Day  29 for the subjects who complete the  study. 
The mean  (±SE)  of the subject  acceptability  score  will be tabulated for  Days  1, 15, and 29. 
Pending data availability, the association between subject preference for treatment attributes and  
subsequent  acceptability  and satisfaction  will be evaluated  separate  for outcome  (effectiveness/safety)  
and other  attributes  (duration, frequency of use,  mode of  intake). 
Safety: 
All safet y analyses  will be conducted using the  Safety Population and will be descriptive  in nature. 
Study drug exposure and study drug compliance will be calculated. The duration of study drug exposure, 
total dose received  and percent compliance will be summarized.  
Medical history, physical examination, demographics and baseline characteristics will be summarized 
and presented. Medical history will be presented by MedDRA system organ class and preferred term, 
summarizing the proportion of subjects who have a condition noted. Results from the baseline physical 
examination will  be summarized by body system  as recorded  in the eCRF.  
Radius  Health,  Inc. Confidential  
Study  BA058 -05-022, Amendment  1, 18 March  2019  Page  15 of 62  
  
Descriptive statistics for laboratory data (including serum calcium  and albumin), vital signs (including  
orthostatic BP), and ECGs will be provided by visit and time point (when applicable). For laboratory 
data, vital signs and ECGs, absolute results and changes from baseline (and changes from predose for 
ECG  heart  rate)  will be presented.  
Sample  Size and Power  Calculation: 
The study being performed  is a hypothesis generating  study and the  sample size is based  on previous 
trial experience without a formal  power calculation.  
Statistical  methods:  
The log transformed AUC 0-t, AUC 0-inf, and C max will be compared among the visits, using Day 1 as the 
reference in the comparison. Point estimates and 90% CIs for differences in PK parameter values 
between  visits will be obtained. 
Summary tabulations will display the number of observations, mean, SD, median, minimum, and 
maximum for continuous variables,  and the  number and  percent per  category  for categorical data.  
Demographics and baseline characteristics of the subject population will be summarized. Summary  
tables, including frequency counts or descriptive statistics, as appropriate, will be prepared for AEs, 
serious AEs (SAEs), AESIs, AEs resulting in discontinuation of treatment or withdrawal from the study, 
and changes in clinical laboratory tests. In addition, subject listings will be presented for AEs, vital 
signs,  clinical  laboratory  tests, ECGs,  local  tolerance,  and user experience assessments.  
Radius  Health,  Inc. Confidential  
Study  BA058 -05-022, Amendment  1, 18 March  2019  Page  16 of 62  
 1. INTRODUCTION 
1.1. Background  
Human parathyroid hormone (PTH) is a naturally occurring 84 amino acid hormone and is 
primarily a regulator of calcium homeostasis ( Mannstadt 1999). PTH acts directly on bone to 
increase calcium  resorption, on the gastrointestinal system  to increase  calcium  absorption, and 
on the kidney to increase calcium reabsorption and 1,25-dihydroxyvitamin D production. In turn, PTH levels are tightly regulated by calcium and vitamin D levels. When given intermittently at low doses, PTH has a well-documented anabolic effect on bone, and can increase bone mineral  density  (BMD) in a number of intact  animal  models and in osteoporotic 
patients  (Dempster  1993).  
Abaloparatide (marketed  as TYMLOS
® in the United  States  [US]) was approved for use on 28 
April 2017 in the US for the treatment of postmenopausal women with osteoporosis at high risk for fracture. Abaloparatide is a novel, synthetic, 34 amino acid peptides designed to be a potent and selective activator of the PTH/PTH -related protein (PTHrP) type 1 receptor 
(PTHR
1) signaling pathway  with 41% homology to PTH[1 –34]) and 76% homology to human 
PTHrP[1 –34]. Abaloparatide is differentiated from PTH and PTHrP ligands based on its high 
affinity  and > 1,000- fold greater  selectivity  for the G protein-coupled (RG) vs the non-G 
protein-coupled (R0) conformation of PTHR 1 (Hattersley 2016). Differential PTHR 1-RG 
binding with abaloparatide results in potent and transient intracellular cyclic AMP (cAMP) 
signaling. In nonclinical studies, the transient PTHR 1 activation with abaloparatide strongly 
favors bone anabolism with a limited effect on bone resorption ( Makino 2015). Thus, 
abaloparatide was developed  with the expectation  that it would be effective  at increasing  BMD  
and reducing fracture in individuals with osteoporosis, but with a limited effect on bone 
resorption and a reduced  risk of hypercalcemia.  
TYMLOS  is supplied in a single- patient -use prefilled  pen that delivers  80 μg of abaloparatide 
as a subcutaneous (SC) injection  into the periumbilical region of the abdomen. Abaloparatide 
administered as a SC injection is referred to throughout this document as abaloparatide- SC. 
RADIUS, in collaboration with 3M, has developed a short wear time intradermal method of 
administration  for abaloparatide to provide an alternative  route of administration  that may be 
preferred  by some patients,  thus, reducing a barrier  for anabolic therapy. This is referred  to as 
the abaloparatide- solid  Microstructured  Transdermal  System  (abaloparatide- sMTS).  
Abaloparatide- sMTS  is a drug device combination product consisting of Abaloparatide:  ZnCl 2 
, HCl , coated onto the sMTS array and contained within the 
fol
lowing packaging  system:  
• The primary  packaging  components with a delivery  function includes: 
− An array  patch for adhering the drug formulation -coated  sMTS array  to the skin 
− An insert  that holds and protects  the coated array  patch and  inserts it into  an 
applicator  
• The primary  packaging  components with a protective function includes: 

Radius  Health,  Inc. Confidential  
Study  BA058 -05-022, Amendment  1, 18 March  2019  Page  17 of 62  
 − A pod that holds the insert  
− A lid heat  sealed to  the edges of the pod 
• The secondary  packaging  includes: 
− A desiccant  
− A foil  patch, heat  sealed, that contains  the sealed pod  and desiccant.  
The applicator is a spring powered device that, when pressed against the skin of the thigh, 
inserts  the drug formulation- coated  sMTS  array  tips into the dermis  at a predetermined  force.  In 
contrast to traditional transdermal delivery systems, the sMTS array penetrates the stratum corneum to deliver  the drug formulation  following a short wear  time (5 minutes).  
 
1.1.1. Disease  and Study  Drug  Background 
Osteoporosis is a systemic skeletal disease characterized by low bone mass and  
microarchitectural  deterioration  of bone tissue  that leads  to enhanced  fragility  and increased  risk 
of fractures (Rizzoli 2001). This disease is characterized by low BMD and fractures. The fractures associated with the greatest morbidity and mortality, as well as economic burden to society, together make up the clinically significant and medically relevant group termed major 
osteoporotic fractures. In the US, there are an estimated 2 million osteoporotic fractures annually ( Litwic 2014). The number of osteoporotic fractures is projected to increase in both 
men and women by more than 3-fold over the next 50 years as a result of the aging population (WHO  2007 ). 
Spinal fractures have also been associated with poor outcomes and high mortality rates ( Suzuki 
2008). It has been reported that once a patient had sustained a vertebral fracture, the risk of a 
subsequent vertebral fracture increases by >300% and the risk of a subsequent hip fracture increased by 200% ( Black 1999). Additional studies have shown that almost half of the patients 
with a prior vertebral fracture will experience additional vertebral fractures w ithin 3 years, many 
within the first year ( Robinson 2002; Lindsay 2001). Those patients who sustained a vertebral 
body fragility fracture showed a prolonged course that can lead to significant disability even one 
year later ( Suzuki 2008). Patients with a d iagnosis of osteoporosis who have had any fracture 
have an 86% increase in their risk for another fracture ( Kanis 2004). With the severity of these 
implications, prevention of a secondary fracture has become a primary focus from a patient care 
and societal  standpoint. 
Major  osteoporotic fractures  (those of the wrist,  shoulder, hip and clinical  spine) account  for 94% 
of the fracture risk for women with low or minimal trauma ( Ensrud 2016 ). Major osteoporotic 
fractures contribute to accumulated frailty such that the Frailty Index is significantly larger in  
those elderly women who have experienced a major osteoporotic fracture. As a result, these 
women have worsening frailty and greater morbidity after a major osteoporotic fracture ( Li 
2015). The Frailty Index was associated with a predicted increase in the risk of falls, fractures,  
death and overnight hospitalizations ( Li 2014). Consequently, prevention of clinically significant 
and medically  relevant major  osteoporotic fractures will  reduce health care costs and benefit 
Radius  Health,  Inc. Confidential  
Study  BA058 -05-022, Amendment  1, 18 March  2019  Page  18 of 62  
 postmenopausal women due  to reduced  frailty,  reduced  risk of falls,  fractures,  hospitalizations  
and death.  
Bone remodeling occurs through the action of osteoclasts, which are involved in the resorption 
of bone followed by the formation of new bone by osteoblasts. In addition to continued use of calcium and vitamin D, the current therapeutic approach to the treatment of osteoporosis through inhibition  of bone resorption includes agents  such as bisphosphonates ( Rosen  2005
), or 
the monoclonal antibody denosumab, that inhibits the action of osteoclasts by binding to receptor activator of nuclear factor kappa-B ligand. An alternative approach has been to tip the balance between osteobla stic bone formation and osteoclastic resorption through the use of 
parathyroid hormone receptor  modulation using teriparatide  (rhPTH[1 –34]). 
Until recently, teriparatide has been the only approved osteoporosis treatment in which the major mode of action is stimulation of bone formation (anabolic) rather than suppression of bone resorption. The efficacy  of teriparatide  has important limitations  related  to its delayed  and 
modest effects on increasing BMD at the total hip and femoral neck; and decreasing BMD at  
the distal 1/3 radius. The increase in cortical porosity that can occur may result in maladaptive effects on cortical bone microarchitecture ( Bilezikian 2007
). Abaloparatide has been evaluated  
in a number of nonclinical and clinical studies for its potential as a novel treatment for  
osteoporosis. Based on the biology of the PTH 1 receptor signaling pathway, abaloparatide was 
designed to have less resorptive and hypercalcemic effects than PTH, resulting in a greater net  
anabolic effect.  
 
1.1.2. Study  Drug  Development  
 
1.1.2.1. Nonclinical Studies  
A comprehensive nonclinical program including dermal tolerance, dermal sensitization, and 
general toxicology studies have been conducted in multiple species (rat, guinea pig, rabbit, minipig and monkey) for abaloparatide-SC and is considered supportive for abaloparatide- sMTS.  
Additionally, dermal tolerance, dermal sensitization, and general toxicology studies with abaloparatide-sMTS are ongoing or planned. The findings from the completed studies support the conclusion that abaloparatide- sMTS is well tolerated, with no new significant safety risks  
identified as compared to abaloparatide-SC. Full details of the nonclinical development program for abaloparatide are provided in the Investigator’s Brochure (IB).  
 
1.1.2.2. Clinical Studies  
There are 19 completed or ongoing clinical studies which comprise the abaloparatide- SC 
(subcutaneous) and the abaloparatide-sMTS (transdermal) clinical development programs. The 
abaloparatide- SC clinical  trial program consists  of 11 completed  clinical  trials,  including a large 
pivotal  Phase  3 study  (BA058-05-003) followed  by an open- label  extension  (BA058 -05-005). 
The abaloparatide- sMTS  clinical trial program consists of 4 completed Phase 1 and Phase 2 
studies, and an ongoing Phase 1 study (BA058- 05-015) to select an optimized formulation and 
dose for abaloparatide-sMTS to be used in the Phase  3 study. 
Radius  Health,  Inc. Confidential  
Study  BA058 -05-022, Amendment  1, 18 March  2019  Page  19 of 62  
 Additional details  for the completed  clinical  studies and  the ongoing study BA058-05-015 can  
be found in the most recent  IB. 
 
1.1.2.2.1. Abaloparatide- SC 
In the pivotal Phase 3 study (BA058-05-003, the ACTIVE trial), 2,463 postmenopausal 
osteoporotic women were rand omized to receive daily 80 µg abaloparatide -SC (n=824), placebo  
(n=821), or teriparatide 20 µg (n=818) (rhPTH 1-34) for 18 months. In this trial, abaloparatide- SC and teriparatide significantly reduced the risk of new morphometric vertebral fractures, by 
86% and 80%, respectively, compared to placebo. Abaloparatide-SC significantly reduced nonvertebral, major osteoporotic and clinical fractures compared to placebo. Compared to teriparatide, abaloparatide significantly reduced major osteoporotic fractures. The Kaplan -Meier  
plots indicate an early and sustained fracture risk reduction of nonvertebral, major osteoporotic and clinical  fractures  with abaloparatide- SC treatment.  Abaloparatide- SC was generally  safe with 
acceptable tolerability in postmenopausal women with osteoporosis; the most common adverse reactions  (incidence ≥ 5%) were  hypercalciuria, dizziness,  nausea,  headache and palpitations.  
Consistent with reduced abaloparatide- SC-mediated calcium mobilization, the rates of  
hypercalcemia  were  lower  in the abaloparatide- SC group compared  to the teriparatide  group. 
In the ACTIVExtend  trial (BA058-05-005), subjects who were in the abaloparatide- SC or 
placebo arms were transitioned to oral alendronate 70 mg weekly. Subjects who received 18 months of abalopa ratide -SC followed by 6 months of alendronate experienced  no new 
morphometric vertebral  fractures  from  the BA058-05-005 study baseline and continued to have 
statistically significant reductions in nonvertebral, major osteoporotic, and clinical fractures  
when  compared  to subjects who previously received  18 months of placebo  followed by 
6 months of alendronate.  These results  validate  the osteoporosis treatment  paradigm  of build 
(with an anabolic agent), and then maintain and consolidate gains (with an anti-resorptive agent).  
Abaloparatide-SC demonstrated an increase in BMD at the lumbar spine, total hip, femoral neck and ultradistal radius in osteoporosis subjects, consistent with the fracture risk reduction. The results from the ACTIVE trial a nd the first 6 months of the ACTIVExtend trial, together 
with the entire  data set from  the abaloparatide -SC development program, support the safety  and 
efficacy of abaloparatide -SC for the reduction of fractures in postmenopausal women with 
osteoporosis. 
In Study BA058-05-005, after 25 and 43 months of  treatment  (18 months abaloparatide,  
1-m
onth transition, followed by 6 or 24 months of alendronate, respectively), the reductions in 
new vertebral fracture for abaloparatide/alendronate vs placebo/alendronate -treated subjects  
show long-term vertebral fracture reduction of 90% after 25 months and 84% after 43 months. In the ACTIVExtend trial the AEs were comparable between subjects previously treated with abaloparatide- SC and the previous pla cebo  group. 
There have been no cases  of osteosarcoma,  osteonecrosis of the jaw or atypical  femoral  fracture  
in the entire abaloparatide-SC clinical development program. In non-clinical studies, a dose dependent incidence of osteosarcomas was seen in both male and female rats treated with  
abaloparatide- and in a positive control group treated with hPTH  (1-34). 
Radius  Health,  Inc. Confidential  
Study  BA058 -05-022, Amendment  1, 18 March  2019  Page  20 of 62  
 Overall,  the clinical  results  of abaloparatide- SC-mediated  early  vertebral  and nonvertebral 
fracture risk reduction and increases in BMD are consistent with the known anabolic 
mechanism  of action,  changes in bone turnover markers  and nonclinical  results.  
 
1.1.2.2.2. Abaloparatide- sMTS  
To date,  several  different  abaloparatide- sMTS  formulations have been  evaluated  in a total of 4 
Phase 1 studies and 1 Phase 2 study, including an abaloparatide- sMTS PBS formulation  
(abaloparatide phosphate buffered saline [PBS]) and an optimized formulation (abaloparatide 
ZnCl 2∙HCl).  
The abaloparatide-sMTS PBS formulation had similar abaloparatide C max but lower 
abaloparatide AUC than the abaloparatide- SC 80 µg reference treatment. This abaloparatide - 
sMTS formulation was evaluated in 3 completed Phase 1 studies in healthy postmenopausal 
women (BA058-05- 004, BA058-05-006 and BA058-05-008). An overview of the design of 
these studies is provided in Figure 1. These studies were conducted to evaluate the PK, safety,  
and local  tolerability  of different  doses of abaloparatide- sMTS  and to evaluate the impact  of the 
application  site and the duration of application  (wear  time)  on PK, safety,  and local  tolerability.  
A Phase 2, dose-range-finding study, Study BA058-05-007, was also conducted with the abaloparatide-sMTS PBS formulation to evaluate the PK, efficacy, and safety of 3 doses of  
abaloparatide- sMTS (50, 100, and 150 μg) compared to 80 μg abaloparatide -SC and placebo - 
sMTS in postmenopausal women with osteoporosis. An overview of the study design is provided in Figure 1. The results from this study did not support the selection of this abaloparatide- sMTS  PBS formulation  for further clinical  development, although it did provide 
important insights into the exposure-response relationship between abaloparatide- sMTS and  
increases  in BMD.  
BA058-05-015 was a Phase 1 study initiated to select an optimized formulation and dose for abaloparatide-sMTS to be used in the Phase 3 study. From the pharmacokinetic data in this clinical study, it was determined that abaloparatide -sMTS Formulation W- 1 (Abaloparatide:  
ZnCl2 , HCl ) 300 µg applied to the thigh for 5 minutes provides a 
single patch administration option with a similar PK profile (slow absorption with a similar  
time of maximum observed plasma concentration [t
max] and  AUC) to abaloparatide-SC 80 µg 
and is expected to produce similar pharmacodynamic effects on BMD as the marketed  
abaloparatide- SC 80 µg treatment in the clinical setting. Additionally, abaloparatide -sMTS  
Formulation W-1 300 µg applied to the thigh for 5 m inutes had an acceptable safety profile in  
the BA058-05-015 study. 
Full details of the results of clinical trials conducted with abaloparatide -SC and  
abaloparatide- sMTS  are provided in the IB. 
 
1.2. Study  Rationale  
The purpose of this study is to evaluate the a bility of subjects to self -administer 300 µg 
abaloparatide- sMTS  over a period of 29 days based  on analyses  of pharmacokinetic (PK) and 
pharmacodynamic (PD) markers. The systemic exposure will be compared to historical  
exposure after treatment  with abaloparatide SC  as well  as results  from  BA058-05-015, 

Radius  Health,  Inc. Confidential  
Study  BA058 -05-022, Amendment  1, 18 March  2019  Page  21 of 62  
 Cohort 7, where subjects were  treated with the  same product as a single dose by a trained  
healthcare professional. 
 
1.3. Dose  Rationale  
The dose of 300 μg of abaloparatide -sMTS, applied to the thigh for 5 minutes, was chosen 
based  primarily  on the comparability  of its pharmacokinetic profile  to that of the  approved 
drug abaloparatide SC at 80 µg per day  as was demonstrated in study BA058-05-015. 
Radius  Health,  Inc. Confidential  
Study  BA058 -05-022, Amendment  1, 18 March  2019  Page  22 of 62  
 2. STUDY  OBJECTIVES AND  ENDPOINTS  
2.1. Objective 
The primary objective of this study is to evaluate the ability of subjects to self-administer 300 µg 
abaloparatide- sMTS  over a period of 29 days based on pharmacokinetic (PK) and 
pharmacodynamic (PD)  markers.  
 
2.2. Primary  Endpoint  
The primary  endpoint is the systemic  exposure of the drug at Day 1, Day 15 and Day  29. 
2.3. Secondary  Endpoints  
2.3.1. Pharmacodynamic (PD) Endpoints  
• Percent  change of s -PINP  from baseline to Day  15 and Day 29. 
• Change and percent change in serum calcium (albumin -corrected) from baseline to  
each post-dose timepoint.  
• Change and percent change in serum phosphorus from baseline to each post-dose 
timepoint.  
• Change and percent  change in  cAMP  from  baseline to  each  post-dose timepoint.  
2.3.2. Other Endpoints  
• Subject satisfaction and convenience of treatment as measured by Treatment  
Satisfaction Questionnaire  for Medication (TSQM9) at Day  15 and Day  29 
• Subject acceptability measurement (5 -point Likert Scale) at Day 1, Day 15 and 
Day 29 
• Subject preference for treatment attributes at Day 1, Day  15 and Day 29 
• Investigator assessment of signs of local skin reaction using a 4- point scale at Day 1,  
Day 15 and Day  29 
• Subject assessment of symptoms of local skin reaction using a 4- point scale from Day  
1 through Day 29 as recorded in the subject diary  
• Daily  measurement of user errors as  recorded in the subject  diary  
• Daily  measurement  of patch  adhesion as  recorded  in the subject diary. 
2.3.3. Safety  and Tolerability  Endpoints  
AEs,  vital signs (orthostatic  blood pressure,  pulse rate,  body temperature,  and respiration  rate),  
ECG, and laboratory tests (serum chemistry, hematology, coagulation, and urinalysis) will be assessed  as per the schedule of  assessment  (SOA)  (
Table 1 ). 
Radius  Health,  Inc. Confidential  
Study  BA058 -05-022, Amendment  1, 18 March  2019  Page  23 of 62  
 3. STUDY  DESIGN  
3.1. Description  of the  Study  Design  
This is an open-label study to evaluate the usability of the abaloparatide-sMTS by subjects with 
low BMD. The study will consist of a Screening Period (up to 2 months), a Pre- Treatment Period  
(1 week), a Treatment Period (1 month), and a 1 week Follow- Up a fter the last dose of study 
medication. Thus, subjects will be in the study for up to 4 months. Eligible subjects will undergo protocol specified procedures, including BMD (if dual energy x- ray absorptiometry [DXA] was  
done over 12 months prior to Screening) and bone turnover marker assessment. For the purpose of this study, 1 month is equivalent to 30 days. 
All eligible  subjects  will be provided calcium and vitamin D  to ensure that their  daily  intake is 
1,200 mg/day and 800 IU/day, respectively, or a dose determined by the Investigator and 
agreed  by the Sponsor Medical Monitor, according to the subject’s need.  
All subjects will undergo safety, pharmacokinetic, bone turnover marker (s-PINP), and 
assessments of User Errors and Subject Preference Outputs accor ding to the SOA ( Table 1 ). The  
study design is presented in Figure 1, below. 
Figure 1: Study  Design  
 
 
 

Radius  Health,  Inc. Confidential  
Study  BA058 -05-022, Amendment  1, 18 March  2019  Page  24 of 62  
 4. SELECTION OF STUDY  POPULATION  
In order  to participate  in this study, a subject  must meet  all of the following inclusion criteria  and 
none of the exclusion criteria. Subjects who were screened and excluded from this study will be 
recorded  in the eCRF with the reason for the screen failures . 
4.1. Inclusion  Criteria  
Subjects must meet all of the following inclusion criteria:  
1. Healthy  ambulatory  female from  50 to 85 years  of age (inclusive). 
2. Postmenopausal for at least  2 years. Postmenopausal status will be established by a history of 
amenorrhea for at least 2 years, negative serum pregnancy test or an elevated serum follicle- 
stimulating  hormone (FSH)  value of  ≥ 30 IU/L.  
3. BMD T -score based on the female reference range of <-1.0 and >-5.0 at the lumbar spine 
(L1–L4)  or hip (femoral neck or total hip)  by DXA.  Note : Every  effort will  be made to enroll 
subjects with a T -score of -2.0 or lower but > -5.0; for those with scores higher than -2.0, 
preference  should be given to subjects with lower  BMD scores.  
4. Good general health as determined by medical history and physical examination (including 
vital signs), has a body mass index of up to 33 kg/m2, and is without evidence of clinically significant abnormality that may increase the risk associated with study participation or  
investigational product administration, or may  interfere  with compliance or  the interpretation  
of study results, and would make the subject inappropriate for this study in the opinion of the Investigator 
5. Serum calcium (albumin -corrected), i ntact PTH, serum phosphorus, alkaline phosphatase, and 
thyroid stimulating hormone (TSH) values all within the normal range during the Screening Period. Subjects with minor elevations or reductions in serum calcium may be enrolled if serum ionized calcium is normal. Any subject with an elevated alkaline phosphatase value, 
and who meets all other entry criteria would be required to have a normal bone- specific 
alkaline  phosphatase to be enrolled  
6. Serum  25-hydroxyvitamin D values  ≥ 20 ng/mL. 
7. Resting  12-lead electrocardiogram at  screening  shows  no clinically  significant abnormality. 
8. Systolic  blood pressure  is ≥ 100 and  ≤ 155 mmHg,  diastolic  blood pressure  is ≥ 40 and  
≤ 95 mmHg, and heart rate is ≥  45 and ≤ 100  bpm (taken sitting)  
9. No clinically  significant abnormality  of serum  hemoglobin, hematocrit, white blood cells, and  
platelets, or usual serum chemistry, including electrolytes, renal function, liver function and 
serum proteins, that might be expected to interfere with the subject’ s health and/or medical  
treatment during  the study 
10. R
ead,  understood, and  signed the written  informed  consent form  
11. Hemoglobin value ≥ 12.0 g/dL 
Radius  Health,  Inc. Confidential  
Study  BA058 -05-022, Amendment  1, 18 March  2019  Page  25 of 62  
 4.2. Exclusion  Criteria  
Subjects  who meet any  of the following exclusion criteria  will be  excluded  from the  study: 
1. History  of bone disorders (eg, Paget’s  disease)  other  than  postmenopausal osteoporosis 
2. History  of prior external  beam or implant radiation therapy  involving the skeleton, other than 
radioiodine 
3. History of Cushing’s disease, hypo- or hyper-parathyroidism or malabsorptive syndromes 
within  the past  year 
4. History  of significantly  impaired  renal function (serum creatinine > 177 μmol/L  or 
> 2.0 mg/dL). If serum  creatinine is  > 1.5 and ≤ 2.0 mg/dL, the calculated creatinine 
clearance (Cockcroft -Gault) must be ≥ 37 mL/min 
5. History of any cancer within the past 5 years (other than basal cell or squamous cancer of the 
skin) 
6. History  of osteosarcoma at any time 
7. History  of nephrolithiasis or urolithiasis within  the past  5 years  
8. Application site (thigh) compromised by scars, inflammation or skin conditions to an extent that may compromise uniformity of 
abaloparatide- sMTS application or drug delivery (nevi, 
plaques, tattoos, scars, piercing, etc.) 
Medication- related  exclusion  crite ria: 
9. Known history of hypersensitivity to any of the test materials or  related compounds 
10. Prior therapeutic treatment with PTH - or PTHrP -derived drugs, or bone anabolic drugs 
including abaloparatide, teriparatide, or PTH(1-84). Subjects who received abalopa ratide in  
prior Phase 1 studies are not excluded 
11. Prior treatment with intravenous bisphosphonates at any time or oral bisphosphonates within the past year (12 months). Subjects who have received a short course of oral bisphosphonate therapy (3 months or less) may be enrolled as long as the treatment occurred 6 or more months prior to enrollment 
12. Treatment  with fluoride or  strontium in  the past  5 years  or prior treatment  with  gallium nitrate  
or bone- acting  investigational agents at any time 
13. Prior treatment with  calcitonin or tibolone in  the past  6 months 
14. Treatment  with  denosumab within the  past 18 months 
15. Treatment with anticonvulsants that affect vitamin D metabolism (phenobarbital, phenytoin,  
carbamazepine or primidone) or with chronic heparin within the 6 months prior to the 
Screening  Period  
16. Treated with anabolic steroids or calcineurin inhibitors (cyclosporin, tacrolimus) within the 
past 90 days. 
Radius  Health,  Inc. Confidential  
Study  BA058 -05-022, Amendment  1, 18 March  2019  Page  26 of 62  
 17. Prior treatment  with  selective estrogen  receptor  modulators (except  hormone replacement  
therapy) or daily  treatment with  oral, intranasal, or inhaled corticosteroids within the  
12 months prior to the Screening Period. Occasional use of all corticosteroids (for seasonal 
allergies or asth ma) is not exclusionary. Use of low dose oral corticosteroids (eg, ≤ 5 mg/day 
of prednisone or the relative equivalent dose of another corticosteroid) is also not exclusionary. 
18. Participation  in another clinical  trial with any investigational drug or device  within  3 months 
or 5 half-lives of the investigational drug (if known), whichever is longer, of study drug administration.  
Lifestyle -related  exclusion  criteria:  
19. Abnormal nutritional status as assessed by the investigator including abnormal diets and 
excessive or unusual vitamin or herbal intakes; vitamin D intake of ≥ 4,000 IU/day or vitamin 
A intake of ≥ 10,000 IU/day. Short term use  of high doses of vitamin  D to  bolster endogenous 
vitamin D levels for  study entry  during the screening  period is not exclusionary 
20. Active  drug or alcohol dependence or abuse (excluding tobacco or medicinal or recreational  
marijuana use where legal unless there is evidence of abuse) within 12 months of the 
screening  period; or evidence of such abuse (in the opinion of the investigator). 
 
4.3. Subject  Withdrawal  or Termination  
4.3.1. Reasons for Withdrawal or Termination  
Subjects  will be informed that they  have the right to withdraw from the study at any time for  any 
reason  without prejudice to their medical care.  
The Investigator may consider  discontinuing subjects from the study for the following reasons: 
• Severe hypersensitivity to abaloparatide or test  materials  
• Refusal  of treatment  
• Inability  to complete  study procedures  
• Lost to follow-up 
• Adverse events  or laboratory abnormalities  which, in the judgment of the 
Investigator, justifies treatment cessation  
• Serious intercurrent  illness  
• Protocol violations 
• Administrative  reasons  
• Incident  vertebral  or non- vertebral  fragility  fracture 
Radius  Health,  Inc. Confidential  
Study  BA058 -05-022, Amendment  1, 18 March  2019  Page  27 of 62  
 4.3.2. Handling  of Subject  Withdrawals or Terminations  
If a subject  is withdrawn or discontinued from  the study, the reason  for withdrawal  from  the study 
must be recorded in the source documents and on the case report form. All subjects withdrawn 
prior to completing the study should be encouraged to complete study procedures scheduled for the Visit 5 / end of treatment (EOT) (Day 29) visit as soon as possible. All AEs should be followed as described  in Section  7. Subjects  who discontinue or are withdrawn  from  the study 
will not be replaced. Whenever a subject is discontinued prematurely, the Sponsor and the Medical  Monitor must be notified. 
4.4. Concomitant  Medications  
Subjects will be provided with calcium and vitamin D supplements to be administered daily from  
the Pretreatment Period until the end of the Treatment Period. The supplement dose will be determined by the Investigator and agreed by the Sponsor Medical Monitor, according to the subject’s need to ensure that their daily intake of calcium and vitamin D is 1,200 mg/day and 800 IU/day, respectively. The doses and schedule of calcium and vitamin D supplements should be adhered  to and not be changed other than for medical  necessity.  The supplements should be taken  
as instructed by the Investigator. 
For any required concomitant medication, such as statins or antihypertensives, the subject must 
be on a stable  dose for 90 days prior to the first treatment visit (Day  1) and  every  effort should be 
made to maintain a stable  dose during study participation.  
The occasional use of over-the-counter medications at approved doses (eg, ibuprofen or 
acetaminophen) for headache or minor discomfort is allowed. These are to be recorded on the appropriate case report form. Subject s should not take any other medications, including over-the- 
counter medications, herbal medications, or mega-doses of vitamins during the study without the prior approval of the Investigator. 
If it becomes necessary for a subject to take any other medicat ion during the study, the specific 
medication(s) and indication(s) must be discussed with the Investigator. All concomitant 
medications taken during the course of the study must be recorded in the subject’s medical record or source document and transcribed into the eCRF.  
4.5. Prohibited  Medications  
Please refer  to Section 4.2 for medication  related  exclusion criteria.  
Subjects  should not take  any other medications,  including over-the-counter medications, herbal 
medications, or mega-doses of vitamins during the study without prior approval of the Investigator. The occasional use of over-the-counter medications (eg, ibuprofen or acetaminophen) for headache or minor discomfort will be allowed if discussed with the Investigator, recorded in  the source documents, and in the subject’s eCRF.  
Use of corticosteroids for seasonal allergies or asthma is not prohibited. Use of low dose oral corticosteroids (eg, ≤ 5mg/day of prednisone or the relative equivalent dose of another corticosteroid) is also not exclusionary. Subjects who require chronic treatment with either an  
anticonvulsant (phenobarbital, phenytoin, carbamazepine or primidone), or with  heparin  will be 
discontinued. 
Radius  Health,  Inc. Confidential  
Study  BA058 -05-022, Amendment  1, 18 March  2019  Page  28 of 62  
 4.6. Premature Termination  or Susp ension  of Study  
This study may be temporarily suspended or prematurely terminated if there is sufficient 
reasonable cause. Written notification documenting the reason for study suspension or termination will be provided by the suspending or terminating party to the principal investigator, and regulatory authorities. If the study is prematurely terminated or suspended, the principal investigator will promptly inform the Institutional Review Board (IRB) and will provide the reason(s)  for the  termination or su spension. 
Circumstances  that may  warrant  termination or  suspension include, but are not limited  to: 
• Determination  of unexpected, significant,  or unacceptable risk  to subjects.  
• Insufficient  compliance with protocol requirements.  
• Data that are not sufficiently  complete  and/or evaluable.  
• Decision  of Sponsor. 
Study may resume once concerns about safety, protocol compliance or data quality  are addressed  
and satisfy  the Sponsor, IRB and/or Regulatory Agencies, if applicable.  
4.7. Temporary  Suspension of Treatment  
Due to the short nature of the study, temporary suspension of treatment is not an option for the Investigator. Any  subject  that is deemed  inappropriate for continuing treatment  will be withdrawn 
from  the study and the reason will be noted in the CRF.  
Radius  Health,  Inc. Confidential  
Study  BA058 -05-022, Amendment  1, 18 March  2019  Page  29 of 62  
 5. STUDY  DRUG  ADMINISTRATION  AND  MANAGEMENT 
5.1. Study  Medication  
All study medications are for investigational use only and are to be used only within the context 
of this  study, and administration  of treatment  is to be  carried  out as described  in Section  5.5. 
Abaloparatide- sMTS  will be  supplied to the study site by RADIUS.  
5.1.1. Abaloparatide- sMTS  
The abaloparatide- sMTS  is enclosed in a collar assembly for loading onto a spring- loaded  
applicator.  The abaloparatide- sMTS dose  will be  300 µg. 
Abaloparatide-sMTS is stored refrigerated at 2º to 8ºC (36º to 46ºF). The abaloparatide- sMTS  
will be removed  from refrigeration  approximately  1 hour prior to application.  Please refer  to the 
pharmacy  manual  for further details.  
5.2. Packaging,  Labeling  and Storage 
5.2.1. Packaging and Labeling  
Abaloparatide-sMTS and applicators will be supplied to the study site by RADIUS. All 
packaging operations will be performed  in accordance with  Good Manufacturing Practices.  
All study drugs will be labeled with a  caution statement and other information required by local  
Regulatory Authorities.  
5.2.2. Storage 
All study medications  (abaloparatide -sMTS) must  be kept in a secure, limited -access  storage area 
at 2° to 8°C (36° to  46°F) until dispensed for dosing or until returned to the Sponsor. 
For Day 1 (Visit 3), Day 15 (Visit 4) and Day 29 (Visit 5/EOT), when the product is applied during a clinic  visit, the  used arrays  will be  carefully  placed in  a supplied container using minimal 
manipulation and frozen for returning to the manufacturer for further inspection and analysis according to a supplied handling procedure manual. Refer to the pharmacy manual for additional  
details.  
Calcium and vitamin D supplements should be stored according to the manufacturer recommendations on the bottle.  
5.3. Study  Medication  Administration  
Subjects  will be encouraged  to drink 8 ounces of water  1 to 2 hours prior to  dosing.  
Prior to the administration of study drug, the application site will be prepped and cleaned with an alcohol wipe, allowed to air dry, and then examined in order to assure that the area is not compromised. Each application site will be graded according to a 4-point scale by the investigator to assess signs of local skin reactions (at clinic visits; Section 6.6.2.1) and by the subject to assess symptoms of local skin reactions (each day during the treatment period; Section 6.6.2.2), prior to  
abaloparatide-sMTS application, immediately after removal of abaloparatide- sMTS, and at 1 hour 
after abaloparatide- sMTS application . For any  severe local  skin reactions, evaluations by the  
Radius  Health,  Inc. Confidential  
Study  BA058 -05-022, Amendment  1, 18 March  2019  Page  30 of 62  
 subject will continue at 24 hour intervals until the reaction has stabilized or resolved (see 
Section  6.6.2.2).  
Before initial use of abaloparatide-sMTS, the subject will be trained on the Instructions for Use 
and will demonstrate their ability to self -administer the abaloparatide -sMTS with the Investigator  
present. During subsequent applications, the subject will follow the Instructions for Use. It is 
important to note that if any component is damaged, the subject is to be instructed to replace the  
abaloparatide- sMTS patch with a new one and place the damaged patch in a container that was  
provided and to bring this together with the other used and unused abaloparatide- sMTS at the  
next clinic  visit.  Please refer to the  pharmacy  manual for additional details.  
5.4. Treatment Assignment  
All subjects  who sign informed  consent and continue to  meet  eligibility  criteria  for the  study will 
be treated  with abaloparatide -sMTS.  
5.5. Dosing and Administration  
The first self-administration  of abaloparatide- sMTS  will occur at  the study site on Day  1, under 
observation.  
Subjects will be trained by study personnel to self- administer study medication with the  
abaloparatide-sMTS patch and applicator; a single daily dose of 300 µg of abaloparatide- sMTS  
will be applied to the thigh for 5 minutes during the treatment period following the Instructions for Use. Please refer to  the pharmacy  manual for  additional details on study drug administration.  
The subject is to remain under observation for a minimum of 60 minutes after abaloparatide- 
sMTS . On the days when blood sampling is required after study medication administration, the 
subject is to remain at the vicinity of the clinic for the blood collec tions scheduled up to 4 hours 
after 
abaloparatide- sMTS application . Subjects are to be instructed to self- administer abaloparatide- 
sMTS  application at a location where they have the ability  to sit or lie  down.  
At each clinic visit during the Treatment Per iod, any used and unused abaloparatide-sMTS should 
be returned.  
5.6. Treatment Compliance  
To ensure treatment compliance, the Investigator or designee will supervise all study drug 
administration  that occurs  at the site. At each  study  visit,  the Investigator or  designee will review  
subject compliance with study drug administration and will remind the subject of study drug 
dosing requirements.  
Subject  compliance will be ascertained by  using the data entered on  the subject  diaries  as well  as 
the total used and unused abaloparatide- sMTS returned at each study  visit.  
Discrepancies will be discussed with the subjects, documented in the medical charts, and recorded in the eCRF as appropriate. If a subject does not take the required medication or suppl ements (abaloparatide-sMTS, calcium and vitamin D), the reason for the missed dose is to 
be recorded by the subject in the subject diary. 
Radius  Health,  Inc. Confidential  
Study  BA058 -05-022, Amendment  1, 18 March  2019  Page  31 of 62  
 5.7. Drug  Accountability  
The Investigator or designated  site staff will maintain  records  documenting the dates  and amounts 
of the following: 
• Study drug received  at the study site 
• Study drug dispensed to  the subject  
• Study drug returned  by the subject  
• Study drug returned to sponsor/designee or destruction of study drug on site  
Subjects  will be provided with a container  and instructed to return all used  and unused study drug 
to the site for destruction. Study drug will be retained at the site until inventoried by the study 
monitor and approved for destruction or return. The study monitor will verify study drug records and inventory throughout the study. 
Radius  Health,  Inc. Confidential  
Study  BA058 -05-022, Amendment  1, 18 March  2019  Page  32 of 62  
 6. STUDY  PROCEDURES  AND  SCHEDULE  
6.1. Study  Procedures  
6.1.1. Study  Specific Procedures  
The study-specific assessments are detailed in this section and outlined in Table 1 . At Screening, 
any results falling outside of the reference ranges may be repeated 1 time at the discretion of the  
Investigator. 
6.2. Study  Schedule  
This study is comprised of 5 clinic visits with either a sixth visit or telephone call for Follow -up. 
Study assessments are to be performed according to the SOA ( Table 1 ). There is a ± 2 -day 
window for each clinic vi sit. 
The study will consist of a Screening (up to 2 months), a Pre- treatment Period (1 week), a 
Treatment Period (29 days) and a Follow-up Period (7 days). During the Treatment Period, 
subjects will have clinic visits for study -related protocol procedures at Day 1, Day 15 and 
Day 29. The Treatment Period  of the study will be considered  complete when the last subject  
completes  the last clinic  visit.  
6.2.1. Schedule  of Assessments and Procedures  
A comprehensive schedule for  assessments and procedures is  presented in  the SOA ( Table 1).  
Radius  Health,  Inc. Confidential  
Study  BA058 -05-022, Amendment  1, 18 March  2019  Page  33 of 62  
  
Table 1: Schedule  of Assessments 
 
 
 
 
 
 
 
 
 
Procedure   
 
Study  Visit   
 
1  
 
2  
Treatment  Period   
 
6  
3  
4  
5 
 
Visit  Day Screening  
(-67 to -8) Pre- 
Treatment  
(-7 to -1)  
Day 1   
Day 15  Day 29 / End of 
Treatment  
(EOT)  Day 36 
(Follow -up) 
Visit  
Window  
(Days)   
N/A  
± 2  
± 2  
± 2  
± 2  
± 2 
Informed  consent  X      
Verification of  entry  criteria  X      
Physical  examination1 X      
Review  of medical  history2 X      
Symptom  directed  physical  
examination1  X X X X  
Vital  signs3 X  X X X  
Weight  measurement  X X X X X  
Height  measurement4 X      
ECG5 X  X X X  
Urinalysis  (dipstick)6 X  X X X  
Chemistry  blood  collection7 X  X X X  
Serum  calcium, albumin,  
phosphorus8   X X X  
Cyclic AMP9   X X X  
24 hour urine  collection  (for 
calcium:creatinine and 
creatinine  clearance)10  X     
Hematology7 X  X X X  
Coagulation  (PT and PTT)  
blood  collection  X      
PTH  (intact)  X      
25-hydroxyvitamin  D level  X      
1,25-dihydroxyvitamin  D 
level  X      
Estradiol,  FSH X      
Serum  pregnancy  X      
Thyroid stimulating  hormone  X      
Urine  Drug  and Alcohol  Test11 X  X    
Subject training on study drug  
administration, completion of  
subject diary and assessment  
of symptoms of  local  skin 
reactions12   X    
Dispensing  of calcium  and 
vitamin  D supplements   X X X   
Study  drug administration13   Every  day between  Visit  3 and Visit 5,  inclusive   
Collect used abaloparatide - 
sMTS  and swab  for residual  
drug and swab residuals    X X X  
BMD of lumbar spine, total  
hip and femoral  neck  by DXA  
14 X      
Investigator  assessment  of 
signs  of local skin  reaction15   X X X  
Radius  Health,  Inc. Confidential  
Study  BA058 -05-022, Amendment  1, 18 March  2019  Page  34 of 62  
  
 
 
 
 
 
 
 
 
Procedure   
 
Study  Visit   
 
1  
 
2  
Treatment  Period   
 
6  
3  
4  
5 
 
 
Visit  Day  
Screening  
(-67 to -8) Pre- 
Treatment  
(-7 to -1)  
 
Day 1   
 
Day 15  Day 29 /  End of 
Treatment  
(EOT)   
Day 36 
(Follow -up) 
Visit  
Window  
(Days)   
 
N/A  
 
± 2  
 
± 2  
 
± 2  
 
± 2  
 
± 2 
Subject assessment of  
symptoms  of local  skin 
reaction16   Every  day between  Visit  3 and Visit 5,  inclusive  X23 
Subject  assessment  of patch  
adhesion17   Every  day between  Visit  3 and Visit 5,  inclusive   
Subject  assessment of  pain18   Every  day between  Visit  3 and Visit 5,  inclusive   
Subject  assessment  of user 
errors    Every  day between  Visit  3 and Visit 5,  inclusive   
Assessment of subject  
preferences  for treatment  
attributes    X X X  
Assessment of subject  
convenience and satisfaction  
(TSQM9)     X X  
Assessment of subject  
acceptability  (5-point  Likert  
scale)    X X X  
Subject  diary  review19   X X X24  
Document  AEs and 
concomitant  medication20 After  signing  informed  consent  until follow  up visit 
PK draw21   X X X  
Serum  marker of  bone  
metabolism  (s-PINP)  22   X X X  
Drug  supply  / Drug  re-supply    X X   
Drug  Accountability     X X  
1. A complete physical examination includes a review of the following systems: head/neck/thyroid, eyes/ears/nose/throat, respiratory,  
cardiovascular, lymph nodes, abdomen, skin, musculoskeletal, and neurological. Breast, anorectal, and genital examinations wi ll 
be performed when medically indicated. After screening, any clinically significant abnormal findings from the symptom -directed  
physical  examinations should be reported  as AEs.  
2. Including  alcohol  and tobacco  use assessment.  
3. Blood pressure, pulse rate, body temperatu re, and respiration rate are to be recorded predose at each study visit. Only blood 
pressure, pulse rate and respiration rate are to be recorded 1 hour after abaloparatide-sMTS application at each study visit during 
the treatment period. All blood pressure  assessments will be orthostatic. Pulse rate will also be obtained at 15 minutes after  
abaloparatide-sMTS  application  at Day  1 (Visit 3), Day  15 (Visit 4)  and Day 29 (Visit  5/EOT).  
4. Height  is to be measured  at the screening  visit/ Visit  1 in the  standing position  using a medical  stadiometer.  
5. During the Treatment Period, ECGs are to be performed predose after 5 minutes of rest and prior to any blood draw, and 1 hour  
after abaloparatide-sMTS application  on Day 1 (Visit  3), Day 15 (Visit  4) and  Day 29 (Visit  5/EOT).  
6. All routine urinalysis will be performed on a sample freshly voided during the visit and sent to a local laboratory for microscopy  
if test is positive  for micro -organisms via dipstick.  
7. Blood draw for serum chemistry and hematology will be  done during the Screening (Visit 1) and at predose on Day 1 (Visit 3),  
Day 15 (Visit 4)  and Day 29 (Visit 5/EOT).  
8. Blood draw for serum calcium, albumin and phosphorus will be done at predose and at 4 hours after abaloparatide -sMTS  
application  on Day 1 (Visit  3), Day 15 (Visit  4) and Day 29 (Visit  5/EOT).  
9. Blood  draw  for cAMP  taken  predose  and at  30 minutes  after abaloparatide-sMTS  application on Day 1 (Visit  3), Day 15 (Visit  4) 
and Day  29 (Visit 5/EOT).  
10. A 24 hour  urine  collection will  start on Day -8 and complete on the day of the pre-treatment  visit (Day  -7). 
11. All subjects will have a urine drug screen for drugs of abuse and alcohol performed on the Screening Period (Visit 1), and on 
Day 1 (Visit  3). 
12. When  necessary, re-training  may be done  post Day 1 / Visit  3. 
13. Study drug is self -administered daily beginning Day 1 (Visit 3) through Day 29 (Visit 5/EOT), inclusive. On Days 1, 15, and 29,  
subject  will self -administer abaloparatide-sMTS at the  study  site. 
Radius  Health,  Inc. Confidential  
Study  BA058 -05-022, Amendment  1, 18 March  2019  Page  35 of 62  
  
14. BMD measured by  DXA at Screening  visit if most  recent  DXA was done  over 12 months  prior  to screening.  
15. Investigators will perform an assessment of the application site at each clinic visit prior to application of abaloparatide - 
sMTS, 5 minutes after application (ie, immediately upon remova l of the patch), and 1- hour following abaloparatide - 
sMTS application.  Signs  of local  skin reactions will be  assessed using  a 4-point  scale,  as described in  Section  6.6.2.1 . 
16. The subject  will maintain  a diary  to record  their assessment  of symptoms  of local skin  reactions for  29 days beginning  on Day 1 
(Visit 3). The subject will evaluate the application site prior to study drug administration, 5 minutes after application (ie,  
immediately upon removal of abaloparatide-sMTS), and 1 hour after abaloparatide -sMTS application. Symptoms of local skin  
reaction s will be  assessed  using  a 4-point  scale as  described in Section 6.6.2.2 . 
17. Subject  assessment  of patch adhesion immediately  prior  to abaloparatide -sMTS  removal  on each  day of the treatment  period 
from Day 1 (Visit 3)  to Day 29 (Visit  5/EOT).  
18. An assessment  of pain (separate from  the pain question  on the 4-point  scale for local  tolerance)  will be done after  sMTS  
application.  
19. The Subject Diary  will be reviewed by  study  personnel  at each study  visit to ensure  subject  compliance.  
20. AEs and SAEs will be recorded on the case report forms starting from the signing of the informed consent until 7 days after t he 
last dose of study medication. All treatment -related AEs will be followed until resolution or stabilization. Any SAEs that occur  
at any time after completion of the study, which are considered by the investigator to be related to study treatment, must be  
reported  to the Sponsor  or its  designee.  
21. Blood samples for measurement of plasma concentrations of abaloparatide will  be taken at Day 1 (Visit 3), Day 15 (Visit 4) and  
on Day 29 (Visit  5/EOT).  The pharmacokinetic measurements  will be assessed predose  and at  10 minutes,  20 minutes,  
30 minutes,  1 hour,  1.5 hours,  2 hours,  3 hours  and 4 hours after  abaloparatide-sMTS  application.  
22. Blood  samples  for s-PINP  taken within  1-hour prior  to dosing on Day 1 (Visit  3), Day 15 (Visit  4) and Day  29 (Visit  5/EOT).  
23. Asse ssed  only for subjects  with signs  or symptoms  of local skin reactions ongoing as of Day 29. 
24. Subject  will return  diary  to study site. 
Radius  Health,  Inc. Confidential  
Study  BA058 -05-022, Amendment  1, 18 March  2019  Page  36 of 62  
  
6.2.2. Informed  Consent  Process  
Each subject must sign and date a study-specific informed consent form (ICF) before any study 
specific procedures can be performed. The consent forms will comply with all applicable regulations governing the protection of human subjects. An ICF, approved by the sponsor and the site’s IRB must be used. The Investigator or designee must record the date when the ICF was signed in the subject’s source document. 
6.2.3. Assigning  Subject  Numbers  
A unique subject  number will be assigned  to each  subject  on Day  1. The  subject  number will be 
used as the primary  subject identifier  for the remainder of  the study. 
6.2.4. Subject  and Disease  Characteristics  
Subject  and disease character istics  include the following: demographics, medical  history, height, 
and weight. 
Medical history will be elicited from each subject during screening. Based on the medical history, the subject will be assessed for any disqualifying medical conditions as specified in the inclusion and exclusion criteria. The medical history  shall include a complete  review  of systems,  
past medical and surgical  histories, and any allergies.  
6.2.5. Screening  Period (Visit 1;  Days -67 to -8) 
Signed informed consent will be obtained and eligibility  for study entry  assessed. The  following 
baseline screening  evaluations will be performed: 
• Obtain  informed  consent 
• Verify  subject eligibility  
• Comprehensive physical examination 
• Review  of medical  history, including alcohol, tobacco,  and drug use 
• Review  of concomitant medications  
• Orthostatic  blood pressure  and vital signs 
• Height 
• Weight  
• 12 Lead  ECG;  subjects  should be allowed  to rest  for 5 minutes  preceding  each ECG  
• Urine  dipstick  
• Urine drug and alcohol test. The urine will be tested for the following drugs: amphetamines, barbiturates, benzodiazepines, cocaine, ethanol, methadone, opiates, phencyclidine, propoxyphene, and a marijuana  screening  test. 
• Blood draw for serum  chemistry,  hematology 
• Blood draw for coagulat ion testing: PT and PTT 
• Blood draw  for serum pregnancy (if needed) 
• B
lood draw for intact  PTH,  25-hydroxyvitamin D, and 1,25-dihydroxyvitamin D level  
• Blood draw for estradiol,  FSH  and TSH level  
• BMD  assessments of lumbar spine, total hip and  femoral neck  by DXA (if not  available 
from  the previous 12 months) 
• Provide subject instructions for the 24 hour urine collection to be collected beginning Day -8 during the pre- treatment period  
Radius  Health,  Inc. Confidential  
Study  BA058 -05-022, Amendment  1, 18 March  2019  Page  37 of 62  
  
Subjects who do not meet the 25-hydroxyvitamin D entry crite rion may receive vitamin D  
supplementation and be retested. Similarly, subjects with minor elevations of PTH may be 
retested 1 time after vitamin D supplementation. Subjects whose laboratory tests do not fall within  the specified ranges  as detailed  in the inclusion/exclusion criteria  may have the samples  
redrawn  and the tests repeated once during the screening  period. 
 
Although the Screening Period is 60 days, all enrolled subjects must have the following safety laboratory 
results reported within 30 days prior to Day 1 (Visit 3): hematology, serum chemistry (including calcium 
and phosphorus), urinalysis, PTH (intact), 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and serum pregnancy. These laboratory tests must be repeated for subjects who were screen ed more than 30 days 
prior  to Day  1 (first  day of treatment).  A list of  the laboratory  tests can be seen  in 
Table 2 
Adverse events  will be recorded for  each  subject from the time of signing of the informed  
consent. 
 
6.2.6. Pre-treatment  Period  (Days -7 to -1) 
Subjects who are eligible for the study, on the basis of screening evaluations, will enter the 7- day 
Pre-treatment  period of the study. 
• Symptom directed  physical examination  
• Dispense calcium and vitamin D to ensure that daily intake is 1,200 mg/day and 800 
IU/day, respectively, (doses to  be determined  by the Investigator  and agreed  upon by the 
Sponsor Medical Monitor, according to the subject’s need) 
• A 24 -hour urine sample will be collected. Subjects will disc ard the 1st void and begin a 
24-hour urine collection on the day prior to the clinic visit  
• AE and concomitant medications  review  
6.2.7. Treatment  Period  
During the Treatment  Period, subjects will self -administer a  single dose of study medication  
once a day. 
At each clinic visit during this period, recent health status will be obtained, the subject diary 
reviewed, AEs collected and orthostatic blood pressure and vital signs recorded. Laboratory assessments of chemistry, hematology and urinalysis will be obtained at Day 1 (Visit 3), Day 15 (Visit 4)  and Day  29 (Visit 5/EOT).  
Bone turnover marker assessments (s -PINP) will be performed within 1 -hour prior to the 
application of abaloparatide-sMTS on Day 1 (Visit 3), Day 15 (Visit 4) and Day 29 (Visit 5/ EOT).  Results for these labs will not be required prior to dosing. 
6.2.7.1. Visit  3 (Day  1) 
The following assessments will be conducted on Day 1: 
• Symptom directed  physical examination  
• Body temperature taken  predose; orthostatic blood pressure and  vital signs: BP, pulse and 
respiratory  rate taken  predose and 1-hour after abaloparatide- sMTS  application; pulse 
rate 15 minutes after abaloparatide- sMTS application  
• Wei
ght  
Radius  Health,  Inc. Confidential  
Study  BA058 -05-022, Amendment  1, 18 March  2019  Page  38 of 62  
  
• 12-lead ECG, to be taken predose and at 1 -hour after abaloparatide-sMTS application. 
Subjects  should be allowed to rest for 5 minutes preceding each  ECG  
• Urine  dipstick test on urine sample  taken  predose 
• Urine  drug and alcohol test  
• Blood draw  for serum chemistry  and hematology taken predose 
• Blood draw for s- PINP  taken up to  1-hour predose 
• Blood draw for cAMP at  predose and  at 30 minutes  after abaloparatide -sMTS  application  
• Training on use of the abaloparatide -sMTS  
• Subject  self-administers  abaloparatide-sMTS under the observation of the Investigator 
• Blood draw for serum calcium, albumin and phosphorus at predose and 4 hours after 
abaloparatide- sMTS  application  
• PK draw  done predose and at  10 minutes,  20 minutes,  30 minutes,  1 hour, 1.5 hours, 
2 hours, 3 hours, and 4 hours after  abaloparatide- sMTS  appli cation  
• Collect  used abaloparatide- sMTS and  swab  for measurement  of residual drug 
• AE and concomitant medication  review  
• Dispense study medication  
• Dispense calcium  and vitamin  D supplements 
• Investigator assessment of signs, and subject assessment of symptoms, of local skin reactions at predose, 5 minutes after application (ie, immediately upon removal of abaloparatide-sMTS), and 1-hour following abaloparatide-sMTS application. For any local skin reactions that persist 1 hour after abaloparatide- sMTS a pplication, evaluations 
by the subject will continue at 24 hour intervals until the skin irritation has stabilized or resolved. 
• Prior to dosing, instruct subject on completion of subject diary, including subject assessment of local skin reactions, patch ad hesion, pain, and user errors. This will need to 
be done daily  for 29 days beginning on Visit 3 (Day  1). 
• Collection  of subject preference for treatment attributes and  acceptability  (5-point Likert 
scale)  information 
• Subject  assessment  of pain  
• Subject  assessment  of patch  adhesion immediately  prior to abaloparatide- sMTS removal  
6.2.7.2. V
 isit 4 (Day  15) 
The following assessments will be  conducted on Day 15: 
• Symptom driven physical examination  
• Body temperature taken predose; orthostatic blood pressure and vital signs: BP, pulse and  
respiratory rate taken predose and 1 hour after abaloparatide- sMTS application; pulse rate  
15 minutes after abaloparatide -sMTS application  
• 12-lead ECG, to be taken predose and at 1 hour after abaloparatide-sMTS appli cation.  
Subjects  should be allowed to rest for 5 minutes preceding each  ECG  
• Weight  
• Urine  dipstick  test on urine sample  taken  predose 
• Blood draw  for serum chemistry  and hematology taken predose 
• Blood draw for s- PINP  within 1  hour prior to application  of abaloparatide -sMTS  
Radius  Health,  Inc. Confidential  
Study  BA058 -05-022, Amendment  1, 18 March  2019  Page  39 of 62  
  
• Blood draw for serum calcium, albumin and phosphorus at 4 hours after abaloparatide- 
sMTS  application  
• Blood draw for cAMP  at predose and  at 30 minutes  after  abaloparatide- sMTS  application  
• PK draw  done predose and at  10 minutes,  20 minutes,  30 minutes,  1 hour, 1.5 hours, 2 
hours, 3 hours, and 4 hours after abaloparatide -sMTS application  
• Subject  self-administration  of abaloparatide- sMTS  
• Collect  used abaloparatide- sMTS and  swab  for measurement  of residual  drug 
• AE and concomitant medication  review  
• Drug  accountability  
• Dispense study medication  
• Dispense calcium  and vitamin  D supplements 
• Investigator and Subject assessment of local skin reactions predose, 5 minutes after application (ie, immediately up on removal of abaloparatide-sMTS), and 1 hour following 
abaloparatide-sMTS application. For any administration site reaction, evaluations by the subject will continue at 24 hour intervals until the skin irritation has stabilized or  
resolved. 
• Subject  assessment  of patch  adhesion immediately  prior to abaloparatide- sMTS removal  
• Subject  assessment  of pain  
• Subject  assessment  of user  error  
• Collection  of subject preference for treatment attributes,  acceptability  (5-point Likert  
scale) and convenience  and satisfaction  (TSQM9)  information  
• Review  subject diary  
6.2.7.3. Visit  5 / End of Treatment  (Day  29) 
The following assessments will be conducted on Day 29: 
• Symptom driven physical examination  
• 12-lead ECG, to be taken predose and at 1 hour after abaloparatide -sMTS application. 
Subjects  should be allowed to rest for 5 minutes preceding each  ECG  
• Body temperature taken  predose; orthostatic  blood pressure and  vital signs: BP, pulse 
and respiratory rate taken predose and 1 hour after abaloparatide-sMTS application; pulse 
rate taken 15 minutes after abaloparatide -sMTS  application  
• Weight  
• U
rine  dipstick  test on urine sample  taken  predose 
• Blood draw  for serum chemistry  and hematology taken predose 
• Subject  self-administration  of abaloparati de-sMTS  
• Blood draw for serum calcium, albumin and phosphorus at 4 hours after abaloparatide- sMTS  application  
• Blood draw for cAMP  at predose and  at 30 minutes after  abaloparatide -sMTS  application  
• PK draw  done predose and at  10 minutes,  20 minutes,  30 minutes,  1 hour, 1.5 hours, 
2 hours, 3 hours and 4 hours after abaloparatide -sMTS application. 
• Collect  used abaloparatide- sMTS and  swab  for measurement  of residual drug 
• AE and concomitant medication  review  
• Drug  accountability  
Radius  Health,  Inc. Confidential  
Study  BA058 -05-022, Amendment  1, 18 March  2019  Page  40 of 62  
  
• Bone turnover markers (s-PINP) taken within 1 hour prior to abaloparatide- sMTS  
application  
• Investigator and subject assessment of local skin reactions predose, 5 minutes after 
application (ie, immediately upon removal of abaloparatide- sMTS), and 1 hour following 
study drug administration. For any administration site reaction, evaluations by the subject will continue at 24 hour intervals  until the  skin irritation  has stabilized  or resolved. 
• Subject  assessment of  patch  adhesion immediately  prior to abaloparatide -sMTS removal  
• Subject  assessment  of pain  
• Subject  assessment  of user  error  
• Collection  of subject  preference for treatment  attributes,  acceptability  (5-point Likert  
scale)  and convenience  and satisfaction  (TSQM9)  information  
• Review  subject diary  
6.2.8. Visit  6/Follow up (Day  36) 
Visit 6/ Follow up (Day  36) can be completed  as a clinic  visit or  remotely  through a phone call 
by the study staff. The  following  are the study assessments for Visit 6: 
• Assessment of local tolerance post EOT visit for subjects with ongoing signs or 
symptoms of local skin reactions 
• AE and concomitant medication  review  
6.2.9. Unscheduled Visit  
If the subject returns to the clinic for an unscheduled visit (eg, to follow-up on an abnormal 
laboratory test),  the procedures performed  at this  visit will  be recorded in  the eCRF  and source 
documentation. 
6.3. Vital Signs  and Physical  Examinations 
A comprehensive physical examination  (review  of all body systems),  height, weight, and vital 
signs assessment will be  performed  at Screening. 
A comprehensive physical examination includes a review of the following systems: head/neck/thyroid, eyes/ears/nose/throat,  respiratory, cardiovascular,  lymph nodes, abdomen, 
skin, musculoskeletal, and neurological. Breast, anorectal, and genital examinations will be  
performed when medically indicated. After screening, any clinically significant abnormal findings in physical examinations should be reported as  AEs.  
Height and weight will be  measured  with  shoes off. Height is  to be measured  using a wall 
mounted stadiometer.  
Vital signs include orthostatic blood pressure (systolic and diastolic), temperature (oral), pulse rate, and respiratory rate. These will be assessed following a 5 minute rest (seated or supine). At visits when study drug is administered at the site, vital sign assessments will be collected before  
the dose of study drug and 1 hour after abaloparatide-sMTS application for blood pressure, pulse and respiratory rate. Seated or supine and standing blood pressure measurements wi ll be 
performed  at each  visit during the Treatment  Period. In addition, pulse rate will be  collected  
15 min
utes  after  abaloparatide- sMTS  application. Temperature will only be collected  predose. 
Radius  Health,  Inc. Confidential  
Study  BA058 -05-022, Amendment  1, 18 March  2019  Page  41 of 62  
  
6.4. 12-Lead  Electrocardiogram  
A standard, 12 lead ECG will be performed. Two hard copies of the ECG should be printed and 
signed by the Investigator at the site; the first copy will be kept in  the subject’s medical  chart  and 
the second copy will be kept in the study file for retrospective collection by the Sponsor, if necessary. Any abnormalities should be noted and clinical relevance should be documented. An ECG will be recorded immediately prior to dosing and at 1 hour after abaloparatide- sMTS  
application on Day 1 (Visit 3), Day 15 (Visit 4) and Day 29 (Visit 5). Additional ECGs may be performed  as clinically  indicated.  
6.5. Laboratory Evaluations  
6.5.1. Clinical Laboratory Evaluations 
Hematology, serum chemistry, and urinalysis will be collected at time points indicated in the  
SOA in Table 1 . All clinical laboratory blood and 24 hour urine samples will be sent to the local 
laboratory for analysis and testing. A list of  study clinical laboratory  tests is in  Table 2. 
Although the Screening Period is 60 days, all enrolled subjects must have the following safety laboratory results reported within 30 days prior to Day 1 (Visit 3): hematology, serum chemistry (including calcium and phosphorus), urinalysis, PTH (intact), 25-hydroxyvitamin D, 1,25- dihydroxyvitamin D, and serum pregnancy. These laboratory tests must be repeated for subjects who were  screened more  than 30 days prior to  Day 1 (first day  of treatment).  
Subjects are required to fast for 8 hours prior to  any safety  laboratory assessments at Screening  
and on Days 1, 15 and 29. Subjects are allowed to continue water consumption during these times.  
Table 2: Clinical Laboratory Tests  
 
Hematology Serum  Chemistry  Urinalysis  
(dipstick)a Additional  Tests 
Hemoglobin  Sodium  pH PTH  (intact)  b 
Hematocrit  Potassium  Glucose  25-hydroxyvitamin Db 
White blood cell count 
with differential in  
absolute  counts  Chloride  Protein  1,25-dihydroxyvitamin Db 
Red blood cell  count  Inorganic  phosphorus  Ketones  Urine Drug and Alcohol  
Tests  
Mean  corpuscular  volume  Albumin  Bilirubin  24 hour urine  collection  
Mean corpuscular  
hemoglobin  concentration  Total  protein  Blood  
Mean corpuscular  
hemoglobin  Glucose  Urobilinogen  Estradiolb 
Platelet  count  Blood urea  nitrogen  Specific gravity  TSHb 
Coagulation test Creatinine  Nitrite  FSHb 
Uric acid Leukocytes  Serum  pregnancy  testb 
Radius  Health,  Inc. Confidential  
Study  BA058 -05-022, Amendment  1, 18 March  2019  Page  42 of 62  
  
Hematology Serum  Chemistry  Urinalysis  
(dipstick)a Additional  Tests 
PTb Aspartate aminotransferase  s-PINP  
PTTb Alanine  aminotransferase  cAMP  
 Gamma-glutamyltranspeptidase    
 Creatine phosphokinase    
 Alkaline  phosphatase    
 Total  bilirubin    
 Lactate dehydrogenase    
 Total  Cholesterol    
 Triglycerides    
 Total  calcium    
a) Clinic  only,  if required  by investigator send  to central  lab for microscopy  
b) Only  required  at Screening  
Serum calcium, phosphorus and albumin will be measured predose from the standard chemistry 
panel on Day 1, Day 15 and Day 29, and from a separate blood draw at 4 hours after abalopa ratide -sMTS application on Day 1, Day 15, and Day 29. Blood draw for cAMP will be 
done predose and 30 minutes after sMTS application at Day  1, Day 15 and Day 29. 
In the event of medically  significant, unexplained, or abnormal clinical laboratory  test values,  the 
test(s) should be repeated and followed up until the results have returned to within the normal range or an adequate explanation for the abnormality is found. Clinically significant changes in laboratory tests that occur during the course of the study are to be reported as AEs unless included as part of a reported diagnosis (see Section  7). 
The clinical laboratory  will clearly  mark all laboratory  test values that are outside the normal 
range and  the Investigator will indicate  the clinical  relevance  of these out of range values.  
6.5.2. Serum  Markers  of Bone Metabolism  
Blood samples will be taken within 1 hour predose to measure serum procollagen type I N- terminal propeptide (s -PINP),  a marker of  bone formati on on Day 1 (Visit 3),  Day  15 (Visit 4) 
and Day  29 / EOT (Visit 5). 
6.5.3. Specimen  Preparation,  Handling  and Storage 
The procedures  for the collection,  handling, and  shipping of clinical  laboratory samples  are 
specified  in a separate  Laboratory Manual provided to each clinical site.  
6.6. Imaging Procedures  
6.6.1. Dual  Energy  X-ray Absorptiometry  (DXA)  
Subjects will have areal bone density measurements taken via DXA of the lumbar spine, total hip, femoral neck, at Screening. Lumbar spine scans must include L1 through L4. Hip scans will include the entire proximal femur to about 2 cm below the lesser trochanter. If a DXA is available that  was taken  in the previous 12 months and  meets the  above criteria,  it can be used in 
place of taking a new scan.  
Radius  Health,  Inc. Confidential  
Study  BA058 -05-022, Amendment  1, 18 March  2019  Page  43 of 62  
  
6.6.2. Local Tolerance 
Assessment  of local  tolerance will consist of evaluation  of signs ( Section  6.6.2.1) and symptoms 
(Section  6.6.2.2) of local  skin reactions. 
 
6.6.2.1. Investigator assessment  of signs of local tolerance  
The investigator’s assessment of local tolerance will consist of evaluation of signs of local skin 
reactions,  which  must be performed by a physician or trained evaluator  at designated  study visits.  
During each clinic visit, as indicated in Table 1 , the application site will be evaluated prior to the 
application of abaloparatide-sMTS, 5 minutes after application (ie, immediately upon removal of 
abaloparatide- sMTS),  and 1 hour after abaloparatide- sMTS application . 
Investigators will assess each of the 12 signs of local  skin reaction  using a 4-point scale:  0-none, 
1-mild, 2 -moderate, 3 -severe. The 12 signs for local skin reactions are as follows: erythema, 
edema,  vesiculation, glazed appearance,  erosions, crusting, hyperpigmentation, 
hypopigmentation, scarring, atrophy, bruising, and bleeding. 
If severe local  skin reactions  occur,  investigators may  contact  the Sponsor for further 
instructions. For any severe administration site reaction, the subject will be  instructed to continue evaluations 
of the application site at 24 hour intervals until the skin irritation has stabilized or resolved. Any 
ongoing treatment-emergent local skin reactions noted on Day 29 will continue to be assessed at 24 hour intervals unt il resolved or stabilized.  
 
6.6.2.2. Subject  assessment  of symptoms  of local tolerance 
Study subjects will be instructed to perform a daily self -assessment of symptoms of local skin  
reaction. The application site will be evaluated prior to study drug administration, 5 minutes after application (ie, immediately upon removal of abaloparatide-sMTS), and 1 hour following abaloparatide- sMTS  application on the day of clinic visits, and between visits beginning Day 1 
up until the  scheduled Day  29 or EOT  visit.  
The 5 symptoms of pain, itching, burning, tenderness and swelling will be assessed using a 4- point scale: 0 -none, 1-mild, 2- moderate, 3-severe. If the subject has severe, or worsening, local 
skin reactions or any local skin reactions that have not resolved within the last 48 hours, they should contact the investigator for further instructions; local skin reactions may then be monitored by the subject  every  24 hours until complete resolution. 
6.6.3. Residual  Drug  
Residual drug evaluation from abaloparatide-sMTS which was applied and removed at the site 
will be conducted by 3M. The clinical site will collect only the abaloparatide -sMTS at Day 1,  
Day 15 and Day 29 and ship the used abaloparatide-sMTS to 3M. The abaloparatide- sMTS will  
be placed  into a glass vial and labelled  with subject number and visit number by clinic staff.  
Upon removal of the abaloparatide- sMTS, the skin surface will be swabbed to measure residual  
drug and the collected swabs will be shipped by the clinical site to 3M. Refer to the pharmacy manual  for additional details.  
Radius  Health,  Inc. Confidential  
Study  BA058 -05-022, Amendment  1, 18 March  2019  Page  44 of 62  
  
6.6.4. Assessment  of Patch  Adhesion  
The patch is to be assessed by the subject for adhesion immediately prior to the removal of 
abaloparatide- sMTS  at each day  during the treatment period.  Adhesion scores will be  scored  
according  to the following  scoring system  and recorded in the subject diary:  
0 = ≥ 90%  adhered (essentially  no lift off the  skin)  
1 = ≥ 75%  to < 90% adhered (some  edges only lifting  off the skin) 
2 = ≥ 50% to <  75% adhered (less than half of the patch lifting  off the  skin) 
3 = > 0% to < 50% adhered but not detached (more  than half of the patch lifting  off skin without 
falling  off) 
4 = 0% adhered – patch detached  (patch completely  off the skin) 
 
6.6.5. Assessment  of Subject  Reported  Outcomes  
The proposed study will be the first to generate user experience data for abaloparatide in the context of a clinical study. Discontinuation rates are particularly high with available osteoporosis therapies regardless of the mode of intake. Abaloparatide will be the first osteoporosis treatment delivered  through a patch  and could have potential to  improve compliance. Previous studies have 
suggested that microneedle patches have a greater acceptabili ty when compared with the 
traditional intramuscular hypodermic injections ( Norman 2014) and may be ideal for subject 
adherence as they do not stimulate nerves that are associated with pain ( Ita 2015). The additional 
endpoint assessment will determine wheth er the abaloparatide -sMTS is well tolerated with  
minimal impact on  subject reported outcomes and improved adherence. 
Acceptability -Given the low acceptability of osteoporosis medications and subject perception of 
benefit/risk, an evaluation of acceptability will be carried out. There is currently no specific instrument with psychometric validation for “acceptability.” Studies including teriparatide have provided a single question “Is this medication acceptable to you.” ( Rouphael 2017). General  
acceptability  will be measured using a 5-point Likert- like scale. One being the least  
acceptable/negative experience to 5 being the most acceptable/positive experience. Acceptability  
will be assessed after  abaloparatide- sMTS application  on Day  1, Day 15 and Day 29. 
Question posed directly  to the subject:  
• “On a scale of 1 (least  acceptable/negative experience)  to 5 (most  acceptable/positive 
experience),  how would you rate this  treatment.” 
 
Subject preference of treatment attributes -While some subject reported outcomes may be 
treatment related, subjects’ preference regarding osteoporosis treatment is likely to impact their  
perception of the treatment and their behavior. As such subject preference and value for drug 
attributes  will be measured  after  abaloparatide -sMTS  application on Days  1, 15, and  29. The  data 
collected  will help identify which factors  may  affect  subjects’  perspectives  on risk/benefits. 
Further, which subject types may be more likely to find treatment acceptable based on value they place on vario us attributes.  
Question posed directly to the subject : 
• “Which  attributes of the treatment  do you find most favorable for you?” 
Radius  Health,  Inc. Confidential  
Study  BA058 -05-022, Amendment  1, 18 March  2019  Page  45 of 62  
  
• “Which  attributes of the treatment  do you find least favorable?” 
 
Treatment Satisfaction Questionnaire for Medication (TSQM) -Treatment satisfaction will be  
measured  with the psychometrically  validated  treatment satisfaction  questionnaire for medication  
short form  (TSQM -9). TSQM  has been  previously used  in osteoporosis studies ( Palacios  2015) 
to assess satisfaction  in post-menopausal women  with osteoporosis ( POSSIBLE  US Study).  
TSQM is associated with discontinuation rates ( Bharmal 2009). The 9- item questionnaire  
contains 3 domains: effectiveness, convenience, and global satisfaction. While the side effect  
domain is  not included, any  unpleasant experiences  with a medication  are likely  to be captured in  
the TSQM global satisfaction items. As a result, the TSQM -9 allows for subjects to weigh the 
pros and cons of medication a nd the less favourable aspects of subjects’ experiences with their  
medications would be captured. The TSQM-9 domain scores range from 0 to 100 with higher 
scores  representing  higher satisfaction  on that domain. Score can  be calculated  overall  or for 
each d omain. Only the convenience and global satisfaction domain will be assessed for the 
current  study as effectiveness  evaluation  is not relevant  given the short follow-up time.  
Measurements will be done after abaloparatide- sMTS  application on Day 15 and 29. See 
appendix for the questionnaire. 
6.7. Discontinuation  from  the Study  
Subjects may  voluntarily discontinue from  the study for any  reason  at any time.  
6.7.1. Withdrawal of Consent  
Subjects may  voluntarily withdraw consent to participate in the study for any reason at  any time.  
Withdrawal of consent occurs only when a subject does not want to participate in the study 
anymore and does not want any further visits or assessments and does not want any further study related  contact.  
If a subje ct withdraws consent, the Investigator must make every effort to determine the primary 
reason for this decision and record this information. Further attempts to contact the subject are not allowed unless safety findings require communicating or follow-up. The Sponsor may retain 
and continue to use any  data collected before consent was withdrawn. 
6.7.2. Early  Study  Termination  
The study can be terminated at any  time for any reason  by the Sponsor. Should this be necessary,  
subjects should be seen as soon as possible and treated as a prematurely withdrawn subject. The 
Investigator may be informed of additional procedures to be followed in order to ensure that adequate consideration is given to the protection of the subject’s interests.  
The Investigator will be responsible for informing IRBs  of the early  termination  of the study. 
Radius  Health,  Inc. Confidential  
Study  BA058 -05-022, Amendment  1, 18 March  2019  Page  46 of 62  
 PLEASE SEE THE STUDY OPERATIONS MANUAL FOR DETAILED INSTRUCTIONS  
ON REPORTING OF SAEs, INCLUDING EMERGENCY CONTACT  INFORMATION (eg, 
FAX,  EMAIL  OR TELEPHONE  CONTACT NUMBERS)   
7. ADVERSE EVENT AND SERIOUS ADVERSE EVENT  
DOCUMENTATION  
 
7.1. Evaluation  of Safety  
Timely, accurate, and complete reporting and analysis of safety information from clinical studies 
are crucial for the protection of subjects and is mandated by Regulatory Agencies worldwide. All  
clinical studies sponsored by RADIUS will be conducted in accordance with Standard Operating Procedures  that have been  established  to conform to regulatory requirements  worldwide to 
ensure appropriate reportin g of safety  information. 
All AEs are collected from the time of signing the informed consent until 7 days after last dose 
of investigational product. At any time after 7 days from the last dose of study treatment, the investigator may  report  any SAE  that he/she believes is  possibly related  to study treatment.  
Where possible, a diagnosis rather than a list of symptoms should be recorded. All AEs should be captured on the appropriate AE pages in the eCRF and in source documents. The Investigator 
will as sess the relationship of all AEs to  the study drug. 
7.1.1. Adverse Event  
An AE is any untoward medical occurrence in a clinical investigation subject administered a 
pharmaceutical product and that does not necessarily have a causal relationship with this treatmen t. An AE can  therefore  be any unfavorable and unintended sign (including an abnormal 
laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational)  product, whether or not related to  the medicinal  (investigational)  product 
AEs could include: 
• Worsening (change in nature, severity,  or frequency) of conditions present  at the 
onset of the study 
• Intercurrent illnesses  
• Drug  interactions  
• Events related  to or possibly related  to concomitant medications  
• Clinically  significant abnormal laboratory values (this  includes significant shifts  from  
Baseline within the range of normal that the Investigator considers to be clinically important)  
• Clinically  significant abnormalities  in physical examination,  vital signs, and  weight 
An abnormal laboratory value will not be assessed as an  AE unless it requires a therapeutic 
intervention or is considered by the Investigator to be clinically  significant.  
When possible, a clinical diagnosis for the study assessment should be provided rather than the abnormal test  result  alone (eg,  urinary  tract infection, anemia). In the absence of a diagnosis, the 
Radius  Health,  Inc. Confidential  
Study  BA058 -05-022, Amendment  1, 18 March  2019  Page  47 of 62  
  
abnormal study assessment itself should be listed as the AE (eg, bacteria in urine or decreased  
hemoglobin). 
Determination  of clinical  significance must be made by the Investigator.  
All skin reactions at the application site reported by the subject and investigator, expected or 
unexpected, and regardless of severity will be reported as AEs and should include reference to the application site. Events of ulcer, eschars, and non-healing wounds at the application site will be evaluated as an adverse event of special interest (Skin AESI). Skin AEs that occur at other  
locations of the body should be reported  as AEs  as appropriate but are  not to be recorded/entered  
using phrases such as ‘at the application site’, ‘involving the application site’, etc., to ensure the phrase ‘application site’  is used exclusively for the sites  of study drug administration.  
7.1.2. Serious  Adverse Event  (SAE) 
An SAE  is any  AE that  results in any of the following: 
• Death  
• Life-threatening: The  term “life -threatening” in the definition  of “serious” refers  to an 
event/reaction in which the subject was at risk of death at the time of the  
event/reaction; it does not refer to an event/reaction which hypothetically might have caused  death if it were  more  severe.  
• Hospitalization  or prolongation of existing hospitalization.  
• Persistent or significant disability/incapacity (ie, substantial disruption of the ability  
to conduct normal life function). 
• Congenital anomaly/birth  defect.  
• Important medical events that may not result in death, are life -threatening, or require 
hospitalization may be considered serious when, based upon approp riate medical  
judgment, they may jeopardize the subject and may require medical or surgical 
intervention to  prevent one of the outcomes listed in  this definition. Examples  of such  
medical events include allergic bronchospasm requiring intensive treatment in an  
emergency room or at home, blood dyscrasias or convulsions that do not result in subject  hospitalization, or the development of drug dependency or drug abuse.  
All AEs of osteosarcoma will be reported  as SAEs.  
All treatment related AEs/SAEs noted on the follow-up visit must be followed until resolution 
(subject has returned to baseline status of health) or until stabilization (the Investigator does not expect  any further improvement or worsening of the reported event),  or until the subject is lost  to 
follow-up. 
7.1.3. Recording  an Adverse Event  
All AEs/SAEs spontaneously reported by the subject and/or in  response to an open question from  
study personnel or revealed by observation, physical examination, or other diagnostic procedures  
must be recorded in  the source document and entered into the electronic database.  
Planned hospital admissions or surgical procedures for an illness or disease that existed before the subject was enrolled in the study are not to be considered AEs unless they occur  at a time  
Radius  Health,  Inc. Confidential  
Study  BA058 -05-022, Amendment  1, 18 March  2019  Page  48 of 62  
  
other than the planned date or the pre- existing illness or disease worsens after enrollment into the  
study. 
For both serious and non-serious adverse events,  the Investigator must determine  the intensity  of 
the event and the relationship of the event to study drug administration. Intensity for each AE 
will be defined according to the following criteria:  
 
Intensity  Definition  
 
Mild  Awareness of sign or symptom, but easily tolerated.  
 
Moderate  Discomfort  enough to cause  interference 
with normal daily  activities.  
 
Severe  Inability  to perform normal daily activities.  
 
If the intensity of an adverse event changes within a day, the maximum intensity should be recorded.  If the intensity  changes  over a longer period of time,  the changes  should be recorded as  
separate events (having separate onset and stop dates for each intensity).  
Relationship to study drug or device, defined as study drug administration will be determined by the Investigator according to the following criteria:  
 
Relationship  Definition  
 
None No relationship  between  the event  and the 
administration of study drug. The event is related to other etiologies, such as concomitant medications or subject’s clinical  state.  
 
Unlikely  The current  state  of knowledge indicates  that 
a relationship to study drug administration is unlikely or the temporal relationship is such that study drug administration would not have had any reasonable association  with the 
observed event.  
 
Possible A reaction  that follows a plausible temporal  
sequence from administration of the study drug and follows a known response pattern to the suspected study drug. The reaction might have been produced by the subject’s clinical state or other modes of therapy  
administered  to the subject.  
Radius  Health,  Inc. Confidential  
Study  BA058 -05-022, Amendment  1, 18 March  2019  Page  49 of 62  
  
Relationship  Definition  
 
Probable A reaction  that follows a plausible temporal  
sequence from administration of the study 
drug and follows a known response pattern to the suspected study drug. The reaction cannot be reasonably explained by the known characteristics of the subject’s clinical state or other modes of therapy  
administered  to the subject.  
 
For the purpose of safety analyses, all AEs that are classified with a relationship to study 
medication  administration  of possible or probable will be considered  treatment -related events.  
The AE will be determined to be device-related if it is identified to have had a probable or 
possible causal relationship to the investigational device.  
 
7.1.3.1. Serious  and Unanticipated Adverse Device Effects  for Abaloparatide- sMTS  
An adverse device effect is defined as any adverse event that may or may not be related to the  
investigational abaloparatide- sMTS  device and should be reported  as an AE (Section 7.1.1),  and 
includes AEs resulting from insufficient or inadequate instructions for use, deployment, implantation, installation, operation, malfunction, use error or from intentional misuse of the investigational medical device.  
An unanticipated adverse device effect (UADE) is defined as any SAE on health or safety or any life-threatening problem or death caused by, or associated with, the abaloparatide- sMTS device,  
or any other unanticipated serious problem associated with a device that relates to the rights,  
safety,  or welfare of subjects. 
The Investigator and the Sponsor will immediately conduct an evaluation of any UADE occurring with abaloparatide-sMTS. The results of the evaluation will be reported to the IRB within 10 days of the Investigator and/or the Sponsor becoming aware of the event. If it is determined by the Investigator and the Sponsor to present an unreasonable risk to study participants,  all investigations or parts  of the investigation  presenting that risk  will be terminated  
as soon as possible. Termination will occur not later than 5 working days after the Investigator and the Sponsor makes this determination, and not later than 15 working days after first receiving notice of the event. The Investigator and the Sponsor will not resume an investigation  
terminated  under these conditions without an additional IRB approval. 
7.1.4. Serious  Adverse Event Reporting  
Any SAEs that occur during the study from the time the subject signs the ICF until 7 days after the last dose of study medication must be reported within 24 hours of first awareness of the event by completing and faxing the SAE Form and entering data in the clinical trial eCRF. In addition, all SAEs including all deaths which occur up to and including 7 days after administration of the last dose of study drug, must be reported to the Medical Monitor within 1 working day. SAE forms will be provided to the clinical study site
. The reference safety information for this study is 
included in the IB, which  will be  provided under separate cover to  all investigators.  
Radius  Health,  Inc. Confidential  
Study  BA058 -05-022, Amendment  1, 18 March  2019  Page  50 of 62  
  
Any SAEs that occur at any time after completion of the study, which the Investigator considers 
to be related to study drug, must be reported to the Sponsor or its designee.  
The Investigator must submit the SAE  to the IRB  in accordance with  21 CFR  parts  56 and  312 as  
well as  with applicable local regulations.  Documentation of these submissions must be retained  
in the site  study file. 
7.1.5. Device  Reporting  
Abaloparatide- sMTS  is a drug- device combination product. In order  to fulfil  regulatory reporting  
obligations worldwide the investigator is responsible for the detection and documentation of 
events  meeting  the definition of UADEs that  occur  with abaloparati de-sMTS  (Section  7.1.3.1).  
Any UADEs that occur during the study with abaloparatide- sMTS  from the time  the participant  
signs the ICF  until 30 days after the last dose of study medication must be reported  within  
24 hours of first awareness that the  event meets the definition of a reportable incident by entering  
data in the clinical trial eCRF. Treatment- related UADEs will be followed until resolution or  
stabilization,  the condition is otherwise explained, or  until the  subject  is lost  to follow-up. 
The investigator will comply with the applicable local  regulatory requirements  relating  to the 
reporting to the IRB.  
7.1.6. Follow- up of Adverse Events  
All treatment -related  AEs will be followed with  appropriate medical  management  until resolved  
or stabilized, or the subject is lost to follow -up. UADEs will be followed until their medical 
outcome is determined, with periodic written reports about the status provided to the study 
Sponsor. 
 
7.1.7. Overdose  
An overdose of abaloparatide- sMTS i s the intentional or unintentional application of a dose of 
abaloparatide that is greater  than intended, such  as using multiple patches  on the same day.  
Overdoses must be reported to the Sponsor whether  or not they  result  in an AE/SAE.  In the event  
of an overdose the Investigator should contact the Medical Monitor immediately and closely 
monitor the subject  for AEs and laboratory abnormalities.  No specific treatment is 
recommended;  the investigator will use clinical judgment to treat any  overdose. 
7.1.8. R egulatory  Agency,  Institutional  Review  Board, and Site Reporting  
The sponsor and/or the clinical  contract  research  organization  are responsible for notifying the 
relevant  regulatory authorities/ IRBs of related,  unexpected SAEs.  
The investigator is  responsible for notifying the sponsor, CRO,  and local  IRB,  or the relevant  
local  regulatory authority of all SAEs that occur  at his or her site as required.  
7.2. Study  Completion  and Post-Study  Treatment  
The Investigator must provide follow- up medical care for all subjects who are prematurely  
withdrawn from the study due to a treatment- related adverse event or must refer them for  
appropriate ongoing care.  
Radius  Health,  Inc. Confidential  
Study  BA058 -05-022, Amendment  1, 18 March  2019  Page  51 of 62  
  
7.3. Lost  to Follow -up 
For subjects whose status is unclear because they  fail to appear  for study visits without stating  an 
intention to discontinue or withdraw, the Investigator should show “due diligence” by 
documenting in the source documents steps taken to contact the subject, eg, dates of telephone calls, registered letters, etc. A subject should not be formally considered lost to follow-up until his scheduled  Visit 6/follow -up visit would have occurred.  
Radius  Health,  Inc. Confidential  
Study  BA058 -05-022, Amendment  1, 18 March  2019  Page  52 of 62  
  
8. STATISTICAL  CONSIDERATIONS  
8.1. Statistical  and Analytical  Plans  
A comprehensive Statistical Analysis Plan (SAP)  and a Pharmacometric  Analysis Plan  will be 
completed  and approved prior to database lock. 
 
8.2. Statistical  Hypotheses 
The primary objective of this study is to evaluate the ability of subjects to self- administer 30 0 µg 
abaloparatide sMTS over a period of 29 days based on pharmacokinetic (PK) and 
pharmacodynamic (PD)  markers.  
No formal statistical tests will be  conducted for any of the study endpoints. 
 
8.3. Analysis Datasets  
8.3.1. Population for Analysis 
The primary  population for all safety analyses will be the Safety  Population, which will be 
defined  as all subjects who received  at least  1 dose of study medication.  
The primary  population for PK  analyses  will be  the Pharmacokinetic (PK) Analysis  Population, 
which wil l include all subjects in the Safety Population who have sufficient evaluable plasma 
concentrations to reliably  estimate  1 or more PK parameters.  
 
8.4. Description  of Statistical Methods  
8.4.1. General  Approach  
Baseline is defined  as the last  value obtained prior to the first dose of study medication.  
For categorical data, summary tabulations of the number and percentage of subjects within each 
category of the parameter will be presented. For continuous data, the number of subjects, mean,  
median, standard deviation (SD), minimum, interquartile range (Q1 and Q3), and maximum will 
be presented, unless otherwise specified. 
 
8.4.2. Analysis of the Primary  Endpoint  
The primary  population for the analysis of the PK parameters will be the  PK Analysis  
Population. 
Individual plasma concentrations of abaloparatide will be listed and summarized by visit and 
sampling time. Concentration data will be summarized at each nominal time point with the  
following descriptive statistics: number of subjects, mean, SD, coefficient of variation (CV%),  
median, minimum, and maximum. Individual plasma concentrations will be plotted vs nominal sampling time on linear -linear and log-linear scales by visit. Spaghetti plots of abaloparatide 
plasma  concentrations will also be prepared.  
Radius  Health,  Inc. Confidential  
Study  BA058 -05-022, Amendment  1, 18 March  2019  Page  53 of 62  
  
The following PK parameters  will be  derived: 
 
Parameters  Description  
AUC 0-t Area under the plasma concentration -time curve from time zero to the  
time of the last quantifiable concentration  
AUC 0-inf Area under the plasma concentration -time curve from time zero to  
infinity  
Cmax Maximum observed plasma  concentration 
tmax Time  of maximum observed plasma  concentration  
t1/2 Apparent terminal phase half -life 
λz Elimination  rate constant 
 
All plasma PK parameter calculations will be performed using actual time (or nominal time,  
when  actual time  is not available)  calculated relative to the time of  study drug administration.  PK 
parameters will be determined using non-compartmental methods based on individual plasma 
concentration -time data for abaloparatide. Individual plasma PK parameters will be listed and  
summarized by visit. PK parameters will be summarized with the following descriptive statistics: number of subjects, mean, SD, CV%, median, minimum, maximum, geometric mean (Geo Mean),  and coefficient  of variation of the geometric mean (Geo Mean  CV%).  
Comparisons between the abaloparatide PK parameter values  on Day 15 and on Day 29 vs Day 1 
(based on natural log (ln) -transformed AUC
0-inf, AUC 0-t, and C max) will be conducted. Point 
estimates and 90% CIs for the difference in PK parameter values between visits will be obtained.  
Further details will be  described in the Pharmacometric Analysis Plan. 
 
8.4.3. Analysis of Secondary  Endpoints  
The primary  population for the analysis of the secondary endpoints will be  the Safety  Population, 
unless otherwise specified.  
Pharmacodynamic endpoints 
The change from  baseline,  percentage change from  baseline and ratio  of post- baseline value to  
baseline value in  s-PINP  will be summarized  descriptively  by visit,  together with  the 90% CI. 
The actual values change from baseline values, and the percentage change from baseline values  
for serum calcium (albumin -corrected), serum phosphorus, and cAMP will be summarized using 
descriptive statistics by  visit and  timepoint.  
Local  Tolerance  
Local tolerance is defined as the assessment of signs (investigator) or symptoms (subject) of local  skin reactions.  For the investigator assessment  of signs of local  skin reactions,  the number 
(%) of subjects in each response category of the 4-point scale will be provided per visit and timepoint. The maximum severity of reaction scores will be similarly summarized for each  
response category by visit.  
Radius  Health,  Inc. Confidential  
Study  BA058 -05-022, Amendment  1, 18 March  2019  Page  54 of 62  
  
For the subject assessment of symptoms of local skin reactions, the mean of the local tolerance 
scores across the entire treatment period and at the Follow- Up visit will be calculated  for each  
response category of the 4- point scale per subject by timepoint. The mean local tolerance score 
will be summarized using descriptive statistics by response category and timepoint. Frequency 
counts (and  percentages) for  the maximum severity  of rea ction  scores  for each response category  
by timepoint will be  presented.  
In addition, the subject assessment of symptoms of local skin reactions collected at the clinic visits  will be  separately  summarized, with  the number (%) of subjects in each response c ategory  
of the 4-point scale provided per visit and timepoint. The maximum severity of reaction scores collected at the  clinical visits will be similarly  summarized for  each response category  by visit.  
Subject  Reported  Outcomes:  
• TSQM9 - Global Satisfaction  and Convenience Domains  
− Mean  TSQM -9 score (±standard  error [SE]) for each  domain will be tabulated  for 
Day 15 and Day 29 for the subjects who completed the study 
− Association between improvement in convenience and satisfaction score (TSQM9) and adherence (definition of adherence will be provided in  the SAP)  
• 5-point Likert- like scale of  acceptability  will be tabulated  and summarized  
− Mean  score (±SE) will  be tabulated for  Day  1, 15, and 29 
− Association  between  improvement in  acceptability  and adherence will be  assessed  
• Subject  Preference for  treatment attributes  will be summarized  
− Pending data availability, association  between  subject  preference for treatment  
attributes and subsequent acceptability and satisfaction will be evaluated  
separately for: outcome (effectiveness/safety) and other attributes (duration, frequency  of use, mode of intake). 
Patch  Adhesion Score:  
Frequency counts (and percentages) for the patch adhesion score collected at each clinic visit  
will be summarized by  visit,  along with the  best adhesion  score (ie, lowest patch adhesion score 
per subject)  and the worst  adhesion score (ie, highest patch adhesion score per  subject).  
The mean of the patch adhesion scores collected from Day 1 to Day 29 will be calculated for  
each subject.  The mean  patch adhesion  score will be summarized  using descriptive statistics  for 
the entire treatment period. The mean of each subject’s best adhesion score and worst adhesion 
score will also be summarized.  
Abaloparatide- sMTS  Released  Dose  
Descriptive statistics will be provided to summarize the abaloparatide -sMTS released dose, the 
percentage of released dose to nominal dose, the percentage of release dose to initial abaloparatide-sMTS content, the residual drug amount from abaloparatide-sMTS, the residual drug amount from abaloparatide-sMTS, and the residual drug amount from abaloparatide- sMTS  
and swab, by visit.  
Radius  Health,  Inc. Confidential  
Study  BA058 -05-022, Amendment  1, 18 March  2019  Page  55 of 62  
  
Details  of analyses  will be  described  in the SAP.  
 
8.4.4. Safety  Analyses 
All safety  analyses  will be  conducted using the Safety  Population and will be descriptive in  
nature.  
Study drug exposure and study drug compliance will be calculated.  The duration of study drug 
exposure, total dose received, and percent compliance will be  summarized.  
All AEs will be coded using the current version of MedDRA available at the time of study start. 
The number and percent of subjects who experienced treatment- emergent AEs (TEAEs) will be  
summarized by MedDRA system organ class (SOC) and preferred term. Summaries will also be provided for severe TEAEs, severe related TEAEs, serious TEAEs, serious related TEAEs, TEAEs leading to study withdrawal, drug-related TEAEs (with probable or possible relationship to study drug), and TEAEs by maximum severity (mild, moderate, severe). A summary will also  
be provided most common (≥ 5%) TEAEs.  
Summaries will be provided for Skin and Hypersensitivity AESIs for TEAEs by SOC and 
preferred term, severe TEAEs, severe related TEAEs, serious TEAEs, serious related TEAEs,  
TEAEs leading t o study withdrawal, drug-related TEAEs (with probable or possible relationship 
to study drug), and TEAEs by maximum severity (mild, moderate, severe). A summary will also be provided most common (≥ 5%) TEAEs  for each AESI.  
All AEs  collected prior  to the first  dose of study drug will be  summarized  separately.  
A listing  of subjects who experience a UADE will  be provided. 
Descriptive  statistics  for laboratory data (including albumin  corrected  serum  calcium,  
phosphorus and cAMP), vital signs (including orthostatic BP), and ECGs will be provided by visit and time  point (when  applicable).  For laboratory data,  vital signs and  ECGs,  absolute results  
and changes from baseline will be presented. In addition, laboratory test r esults will be classified  
as above normal limit, within normal limit, or below normal limit. Laboratory shift frequencies  
will be tabulated between the Screening  visit and relevant post- baseline visit(s).  
Concomitant medications will be coded using the World Health Organization (WHO) Drug Dictionary  and summarized by number and percentage of subject using each class and  preferred  
drug term.  
 
8.4.5. Adherence and Retention  Analyses 
The number and percentage of subject who withdraw from the study, with primary reason, will be summarized.  
 
8.4.6. Baseline  Descriptive Statistics  
Medical history, physical examination, demographics and baseline characteristics will be 
summarized  and presented. Medical  history will be  presented  by MedDRA SOC  and preferred  
term, summarizing the proportion of subject who have a condition noted. Results from the baseline physical examination will be  summarized  by body system  as recorded  in the eCRF.  
Radius  Health,  Inc. Confidential  
Study  BA058 -05-022, Amendment  1, 18 March  2019  Page  56 of 62  
  
8.4.7. Interim  Analyses 
There are no interim analyses  planned for this study. 
 
8.4.8. Additional  Subgroup Analyses 
Subgroup analysis  may  be performed  and will be  described  in the SAP.  
 
8.4.9. Multiple  Comparison/Multiplicity  
No formal  statistical tests will be performed, and hence no adjustments  for multiple  comparisons 
will be made.  
 
8.4.10. Tabulation of Individual  Response  Data  
Individual efficacy  and safety  data will be tabulated  as appropriate.  
 
8.4.11. Exploratory Analyses 
Additional exploratory analyses  may  be presented as either  planned (and  described in the SAP)  
or post-hoc to complement the  overall understanding of study results.  
 
8.5. Sample  Size Calculation  
This is a hypothesis generating  study and the sample size is based on previous clinical trial 
experience without a formal power calculation. 
 
 
8.6. Measures  to Minimize  Bias 
Not applicable.  
 
8.7. Enrollment/Randomization/Masking Procedures  
Treatment  will not be blinded. 
Radius  Health,  Inc. Confidential  
Study  BA058 -05-022, Amendment  1, 18 March  2019  Page  57 of 62  
  
9. ADMINISTRATIVE  REQUIREMENTS  
9.1. Ethical Considerations  
This clinical study will be conducted in accordance with the current version of International 
Conference on Harmonization (ICH) Harmonized Tripartite Guidelines for Good Clinical Practice (GCP),  with  applicable local  laws  and regulations, and with  the ethical  principles laid  
down in the Declaration  of Helsinki. 
The Investigator will e nsure that this  study is conducted in full conformity  with Regulations for 
the Protection of Human Subjects of Research codified in 21 CFR Part 50, 21 CFR Part 54, 21 CFR  Part 56, 21CFR Part 312, 21 CFR Part 314 and ICH GCP E6.  
The IRB will review all appropriate study documentation to safeguard the rights, safety, and well-being of the subjects. The study will only  be conducted at sites  where IRB  approval has 
been  obtained. The  protocol, IB, ICF,  advertisements  (if applicable), written  information  given to 
the subjects,  safety  updates, annual progress reports, and any revisions to these  documents will 
be provided to the IRB by the Investigator or RADIUS or designee, as allowable by local applicable laws  and regulations. 
 
9.2. Subject  Information  and Informed  Consent  
The Investigator is  responsible for obtaining written,  informed  consent from  each subject  
interested in  participating in this study  before  conducting any study- related  procedures. 
Written  informed  consent  should be obtained after adequate,  thorough, and  clear  explanation  of 
the study objectives, procedures, as well as the potential hazards of the study. The method of 
obtaining and documenting the informed consent and the contents of the consent will comply with ICH GCP and all applicable laws and regulations and will be subject to approval by RADIUS  or its designee. 
9.3. Investigator  Compliance  
No modifications to the protocol should be made except where the modification is  necessary  to 
eliminate an apparent immediate hazard to human  subjects. RADIUS will submit all protocol 
modifications  as amendments to the required regulatory authorities.  
When circumstances require an immediate departure from procedures set forth in the protocol,  
the Investigator will contact  RADIUS  to discuss the planned course of action.  If possible, contact  
should be made before the implementation  of any changes.  Any departures  from  protocol must 
be fully  documented in the source documentation. 
9.4. Access  to Records  
The Investigator must make the office and/or hospital records of subjects enrolled in this study available for review by site monitors at the time of  each monitoring visit, audit by RADIUS QA 
and inspection by the regulatory agencies. The records must also be available for inspection, 
verification, and copying, as required by applicable laws and regulations, by officials of the 
regulatory health  authorities  (Food and  Drug  Administration  and others).  The Investigator  must 
Radius  Health,  Inc. Confidential  
Study  BA058 -05-022, Amendment  1, 18 March  2019  Page  58 of 62  
  
comply with applicable privacy  and security laws for use and disclosure of information related to  
the research set forth in this protocol. 
 
9.5. Subject  and Data  Confidentiality  
To maintain  subject  confidentiality,  all eCRFs,  study  reports  and communications relating  to the 
study will identify subject by unique subject ID numbers assigned to each subject. As required 
by federal regulations, the Investigator will allow RADIUS and/or its representatives access to  
all pertinent medical records to allow for the verification of data gathered in the eCRFs/SAE  
Forms/source data documents and the review of the data collection process. The Food and Drug Administration (or other regulatory authority) may also request access to all study records, including source documentation, for inspection. 
As applicable, in accordance with the Health Insurance Portability and Accountability Act 
(HIPAA) and associated privacy regulations, a subject authorization to use personally identifiable  health  information may  be required  from  each subject  before  research  activities  
begin. 
Subject confidenti ality is strictly held in trust by the participating Investigators, their staff, and  
RADIUS  and their  representatives. This  confidentiality  is extended  to cover  testing  of biological 
samples  and genetic tests in  addition to the clinical  information relatin g to study subjects.  
Therefore, the study protocol, documentation, data, and all other information generated will be 
held in strict confidence. No information concerning the study or the data will be released to any 
unauthorized third party without prior written  approval of RADIUS. 
9.6. Research  Use of Stored  Human  Samples,  Specimens,  or Data  
With  the subject’s  approval, and  as approved by the site’s IRB,  biological samples  may be stored  
at a centralized facility determined by RADIUS. These samples could be used for retrospective 
biomarker research or analysis of clinical response to therapy and to improve current and future 
treatment outcomes. The storage facility  will maintain the masking  of the identity  of the subject.  
During the conduct of the study, any individual subject can  choose to withdraw  consent to have 
biological specimens stored for future research. When the study is completed, access to study 
data and/or samples will be provided through RADIUS.  
 
9.7. Data  Quality Assurance  
RADIUS or its de signated representative will conduct a study site visit to verify the  
qualifications  of each  Investigator, inspect  clinical  study site facilities  as needed, and  inform  the 
Investigator of responsibilities and procedures for ensuring adequate and correct study documentation. 
The Investigator is required to prepare and maintain adequate and accurate case histories  
designed to record all observations and other data pertinent to the study for each study subject. 
Study data for each enrolled subject will be entered into an eCRF by site personnel using a secure, validated web -based electronic data capture (EDC) application. RADIUS will have read - 
only access to all data upon entry in the EDC application. Study assessment data generated by contracted 3
rd party vendors will be obtained via external data transfers (outside the EDC 
application) and  reconciled  against  confirmatory  data contained  in the EDC  system  by RADIUS’  
Radius  Health,  Inc. Confidential  
Study  BA058 -05-022, Amendment  1, 18 March  2019  Page  59 of 62  
  
designee. External data will be incorporated into Study Data Tabulation Model (SDTM) datasets  
by RADIUS’ designee for RADIUS’ use.  
Instances  of missing,  discrepant,  or uninterpretable data will be queried  with  the Investigator for 
resolution. Any changes to study eCRF data will be made in the eCRF and documented in an 
audit trail, which will be maintained within the clinical database. Changes to external data will be handled exclusively by the 3
rd party  vendor responsible for the data.  
To ensure compliance with GCP and all applicable regulatory requirements, a quality assurance 
audit may be conducted. Regulatory agencies may also conduct a regulatory inspection of this study. Such audits/inspections can occur at any time during or after completion of the study. If an 
audit or inspection occurs, the Investigator and institution agree to allow the auditor/inspector 
direct access to all relevant documents and to allocate his/her time and the time of his/her staff to  
the auditor/inspector to discuss findings and any relevant issues. In the case of an audit or inspection, the Investigator or a delegate will alert RADIUS, as soon as he/she becomes aware of  
the audit or inspection. 
The Investigator and study staff are responsible for maintaining a comprehensive and accurate 
filing system of all study -related documentation that will be suitable for inspection at any time  
by RADIUS,  its designees, and/or regulatory agencies. In  signing this protocol, the Investigator 
understands and  agrees to give access to the necessary  documentation and files.  
 
9.8. Monitoring  
RADIUS is responsible for ensuring the proper conduct of the study with regard to protocol adherence and validity  of data recorded in the clinical database. The study will be  monitored by 
RADIUS or its designee. Monitoring will be done by personal visits f rom a representative of  
RADIUS, or designee (site monitor), who will review the eCRFs, SAE Forms and source documents. The site monitor will ensure that the investigation is conducted according to the protocol design and regulatory requirements.  
 
9.9. Data  Collection  and Management  Responsibilities  
Data collection is  the responsibility  of the clinical  study staff at the  site under the supervision of 
the Investigator. The Investigator is responsible for ensuring the accuracy, completeness, 
legibility,  attributability,  and timeliness  of the data reported.  
RADIUS or its designee will provide the study sites with secure access to and training on the EDC application sufficient to permit site personnel to enter and correct information in the eCRFs  
on the subject for which they are responsible.  
An eCRF will be completed for each subject who receives at least 1 dose of study drug. Nominal 
data, limited to demographics and the reason for screen failure, will be collected for all subjects who sign an ICF but are not randomized, although additional data will be collected if a screen failure experiences an adverse event during while being screened. It is the Investigator's responsibility to ensure the accuracy, completeness, clarity, attributability, and timeline ss of the 
data reported in the subject’s eCRF. Source documentation supporting the eCRF data should indicate the subject’s participation in the study and should document the dates and details of study procedures, AEs, other observations, and subject status. 
Radius  Health,  Inc. Confidential  
Study  BA058 -05-022, Amendment  1, 18 March  2019  Page  60 of 62  
  
The Investigator, or designated  representative, should complete  the eCRF in  a timely  manner  
after information is collected.  
The audit trail entry will show the user's identification information, the date and time of log in, 
the date and ti me of data entry and/or any change or correction to previously entered data, as 
well as the reason  for any  data change. The Investigator must provide formal  approval of all the  
information in the eCRFs, including any changes made to the eCRFs, to endorse the final  
submitted  data for the subjects  for whom the Investigator is responsible. 
RADIUS will retain the eCRF data, queries and corresponding audit trail. A copy of the final archival  eCRF  in the form of a compact  disc or other electronic media  will be provided to the site  
for placement in the  Investigator's study file. 
 
9.10. Study  Records  Retention 
The Investigator will maintain  study documents for  a minimum of 2 years after  the last approval 
of a marketing application in an ICH region and until there are no pending or contemplated 
marketing applications in an ICH region or until at least 2 years have elapsed since the formal discontinuation of clinical development of the investigational product. These documents will be retained for a longer period, however, if required by local regulations. If the Investigator withdraws from the responsibility of keeping the study records, custody must be transferred to a person willing to accept the responsibility and RADIUS must be notified. No records will be destroyed  without the written consent of RADIUS. 
 
9.11. Publication  and Data  Sharing  Policy  
Publication of complete data from the study is planned. It is anticipated that the results of this 
study will be presented at scientific meetings and/or published in a peer reviewed scientific or  
medical journal. A Publications Committee composed of Investigators participating in the study and representatives  from RADIUS  as appropriate will  be formed  to oversee the publication of the 
study results, which will reflect the  experience of all participating  study centers.  
Subsequently, individual Investigators may  publish results  from the  study in compliance with 
their agreement with RADIUS.  
Radius  Health,  Inc. Confidential  
Study  BA058 -05-022, Amendment  1, 18 March  2019  Page  61 of 62  
  
10. LITERATURE  REFERENCES 
 
Barrett -Connor E, Wade SW,  Do TP,  et al. Osteoporos Int (2012) 23: 733. 
Bharmal M, Payne K, Atkinson MJ, Desrosiers MP, Morisky DE, Gemmen E. Validation of an  
abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM -9) among patients on 
antihypertensive medications. Health Qual  Life Outcomes. 2009; 7: 36. 
Black DM, Arden NK, Palermo L, Pearson J, Cummings SR. Prevalent vertebral deformities 
predict  hip fractures  and new  vertebral  deformities  but not wrist  fractures.  Study of Osteoporotic 
Fractures  Research Group. J Bone Miner  Res. 1999; 14(5): 821-828. 
Bilezikian  JP. Anabolic therapy  for osteoporosis. Women’s  Health  (Lond). 2007;3:243-253. 
Dempster  DW,  Cosman  F, Parisien  M, Shen  V, Lindsay R. Anabolic actions  of parathyroid 
hormone on bone. Endocr Rev. 1993;14:690–709. 
Ebeling PR. Osteoporosis in men. New  Engl J Med.  2008;358:1474-1482. 
Ensrud KE,  Blackwell  TL, Cawthon PM,  et al. Degree of Trauma Differs for Major  Osteoporotic 
Fracture  Events in Older  Men Versus Older  Women. J Bone Miner  Res. 2016; 31(1): 204-207. 
Hattersley  G, Dean  T, Corbin BA, Bahar  H, Gardella  TJ. Binding selectivity  of abaloparatide for 
PTH -type-1- receptor  conformations and  effects  on downstream signaling. Endocrinology. 
2016;157:141-49. International Osteoporosis Foundation. Osteoporosis in men. 2014; accessed via 
http://www.iofbonehealth.org/WOD/2014/thematic-report/WOD14-Report.pdf  
Ita, K. Transdermal Delivery o f Drugs with Microneedles-Potential and Challenges. 
Pharmaceutics.  2015; 7(3): 90-105. 
Kanis JA, ￼ O , De Laet C, et al. A meta-analysis of previous fracture and subsequent fracture 
risk. Bone. 2004;35(2): 375-382. 
Khosla S, Amin  S, Orwol l E. Osteoporosis in men. Endocrine Rev. 2008;29:441-464. 
Li G, Thabane L, Papaioannou A, Adachi JD. Comparison between frailty index of deficit accumulation and fracture risk assessment tool (FRAX) in prediction of risk of fractures. Bone. 2015; 77: 107-114. 
Li G, Ioannidis G,  Pickard  L, et al. Frailty  index of deficit  accumulation  and falls: data from  the 
Global Longitudinal Study of Osteoporosis in Women (GLOW) Hamilton cohort. BMC 
Musculoskelet Disord. 2014; 15: 185. 
Lindsay R
, Silverman SL, Cooper C, M D; et al. Risk  of New Vertebral Fracture in the Year  
Following a Fracture.  JAMA. 2001;285(3):320-323. doi:10.1001/jama.285.3.320 
Litwic  A, Lekarz,  Warwick  D, Denniston E.  Distal radius fracture:  Cinderella  of the osteoporotic 
fractures.  Orthop Muscul Syst. 2014; 3:162-8. 
Makino M, Takagi H, Sugiyama H, Kobayashi T, Kasahara Y. Effects of abaloparatide on the 
expression of bone resorption and  formation -related  factors  in osteoblastic  cells;  a comparison 
Radius  Health,  Inc. Confidential  
Study  BA058 -05-022, Amendment  1, 18 March  2019  Page  62 of 62  
  
with teriparatide.  Annual Meeting  of the American  Society  for Bone and Mineral  Research  2015; 
MO0121. 
Mannstadt M, Juppner H,  Gardella TJ. Receptors  for PTH  and PTHrP:  Their  biological 
importance and functional properties. Am J Physiol. 1999; 277:F665-F675 
Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA, Alexandersen P, Zerbini CA, 
Hu M, Harris  AG, Fitzpatrick LA,  Cosman  F, Christiansen  C. Effect  of abaloparatide vs placebo  
on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical 
trial. J Am Med Assoc. 2016;316:722-733. 
Newcombe  RG. Interval  estimation  for the difference  between  independent proportions: 
Comparison of eleven methods. Stat Med. 1998; 17:873-890. 
Norman JJ, Arya JM, McClain MA, Frew PM, Meltzer MI, Prausnitz MR. (2014). Microneedle 
patches:  usability  and acceptability  for self -vaccination  against  influenza.  Vaccine.  2014;32(16): 
1856-1862. 
Palacios S, Agodoa  I, Bonnick S, et al. Treatment satisfaction in postmenopausal women  
suboptimally  adherent  to bisphosphonates who transitioned  to denosumab compared with  
risedronate or ibandronate. J Clin Endocrinol Metab. 2015; 100(3): E487-492. 
Rizzoli  R. Osteoporosis, genetics  and hormones. J Mol Endocrinol. 2001;26:79-94. 
Robinson, CM, Royds M, Abraham A, McQueen MM, Court-Brown CM, Christie J. Refractures 
in patients at least forty -five years old. a prospective analysis of twenty-two thousand and sixty 
patients. J  Bone Joint Surg  Am. 2002; 84-a( 9): 1528-1533. 
Rouphael NG, Paine M, Mosley r, et al. The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV -MNP 2015): a randomised, 
partly  blinded, plac ebo-controlled, phase 1 trial.  Lancet. 2017; 390(10095): 649-658. 
Rosen  CJ. Clinical practice.  Postmenopausal osteoporosis. N Engl J Med.  2005;353:595-603. 
Suzuki N, Ogikubo O , Hansson T . The course of the acute vertebral body fragility fracture: its  
effect on pain, disability and quality of life during 12 months. Eur Spine J. 2008; 17(10): 1380- 1390. 
World  Health  Organization (WHO).  Assessment  of osteoporosis at the  primary  health  care level.  
Summary of a WHO Scientific Group 2007 [16 Feb 2017]. Available from: 
www.who.int/chp/topics/rhuematicrheumatic/en/index.html
 
 
 19-Mar-2019 19:52:39 GMT+0000  Approval 
20-Mar-2019 11:39:53 GMT+0000  Approval 
20-Mar-2019 12:57:03 GMT+0000  Approval  
 
Signature Page for RAD- CLIN -001055 v2.0 
 
 
 
 
 
Signature Page for RAD -CLIN -001055 v2.0 
